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Optochemical Tools For Protein Dimerization In Living Cells 
Abstract 
Fundamental biological processes including cell division, migration, and death, 
are driven by protein interactions. Regulation of protein localization is one of the 
mechanisms cells utilize to control cellular events with high spatial and temporal 
precision. Therefore, several techniques have been developed to provide control of 
protein interactions and localization. A number of elegant approaches employ naturally 
light-responsive proteins, also known as optogenetics, to reversibly induce protein‒ 
protein binding interactions with subcellular precision. However, the application of these 
light-inducible protein systems to various intracellular locations beyond the plasma 
membrane has been limited. Moreover, to achieve sustained interactions in some 
applications, most of these optogenetic systems require continuous illumination, 
increasing the risk of phototoxicity. Another robust and widely utilized technique to 
control protein interactions via small molecules is the chemically-induced dimerization 
(CID) of proteins; the most classic example of this technique being rapamycin-induced 
dimerization. However, the lack of spatiotemporal control and reversibility in this system 
has necessitated the development of new dimerizers in the past two decades. By 
combining light-inducible features with the CID technique, we have created a novel 
platform to rapidly and reversibly induce protein dimerization using light with high 
specificity in living cells. This is accomplished with subcellular spatiotemporal resolution 
using a series of novel, cell-permeable, photoactivatable, and photocleavable chemical 
dimerizers. The modular design of our system has allowed us to tailor the properties of 
our molecules for studying various protein functions and biological pathways inside 
living cells. Furthermore, we demonstrate the utility of our system by applying it to 
manipulate dynamic biological events including organelle transport and spindle assembly 
checkpoint. This work establishes a foundation for optogenetic control over protein 
function and highlights the advantages of a hybrid chemical and genetic approach. We 
envision our tools to be readily adapted to experimentally probe complex signaling 
networks and other cellular processes that depend upon spatiotemporal regulation of 
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Fundamental biological processes including cell division, migration, and death, 
are driven by protein interactions. Regulation of protein localization is one of the 
mechanisms cells utilize to control cellular events with high spatial and temporal 
precision. Therefore, several techniques have been developed to provide control of 
protein interactions and localization. A number of elegant approaches employ naturally 
light-responsive proteins, also known as optogenetics, to reversibly induce protein‒
protein binding interactions with subcellular precision. However, the application of these 
light-inducible protein systems to various intracellular locations beyond the plasma 
membrane has been limited. Moreover, to achieve sustained interactions in some 
applications, most of these optogenetic systems require continuous illumination, 
increasing the risk of phototoxicity. Another robust and widely utilized technique to 
control protein interactions via small molecules is the chemically-induced dimerization 
(CID) of proteins; the most classic example of this technique being rapamycin-induced 
dimerization. However, the lack of spatiotemporal control and reversibility in this system 
has necessitated the development of new dimerizers in the past two decades. By 
combining light-inducible features with the CID technique, we have created a novel 
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platform to rapidly and reversibly induce protein dimerization using light with high 
specificity in living cells. This is accomplished with subcellular spatiotemporal resolution 
using a series of novel, cell-permeable, photoactivatable, and photocleavable chemical 
dimerizers. The modular design of our system has allowed us to tailor the properties of 
our molecules for studying various protein functions and biological pathways inside 
living cells. Furthermore, we demonstrate the utility of our system by applying it to 
manipulate dynamic biological events including organelle transport and spindle assembly 
checkpoint. This work establishes a foundation for optogenetic control over protein 
function and highlights the advantages of a hybrid chemical and genetic approach. We 
envision our tools to be readily adapted to experimentally probe complex signaling 
networks and other cellular processes that depend upon spatiotemporal regulation of 
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CDI   1,1’-Carbonyldiimidazole 
DBU   2,3,4,6,7,8,9,10-Octahydropyrimidol[1,2-a]azepine 
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1H-1,2,3-triazolo-[4,5-b]pyridin-1-ylmethylene]-N-
methylmethanaminium hexafluorophosphate N-oxide 
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Overnight 16 hours 
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Why are we interested in protein-protein interactions? 
Cells are a complex mixture of organic and inorganic contents including 
nucleotides, proteins, lipids, carbohydrates, and other chemicals. These components must 
synchronously and synergistically interact in a highly precise and specific manner to 
constitute proper cell function. The fundamental process of life begins with the central 
dogma; genes encode the information needed to be transcribed and translated into 
proteins, which are the key players within the cell, carrying out the duties specified by the 
genes1.  
Proteins are large biomolecules composed of amino acid residues assembled to 
form one or more long chains. Proteins have diverse functions within organisms 
including catalyzing metabolic reactions, DNA replication, responding to stimuli, and 
transporting molecules from one location to another. The sequence of amino acids 
directly influence how protein folding occurs. The folded structure of a protein 
determines its activity. Some proteins are capable of binding small-molecule substrates 
and other proteins. However, in some cases proteins will bind specifically to other copies 
of itself to form fibrils2. This process often occurs often in structural proteins that consist 
of globular monomers that self-assemble to form rigid fibers. In all living organisms, 
protein-protein interactions (PPIs) are fundamental driving forces in biological processes 
and essential for cellular activity such maintaining homeostasis3. PPIs play crucial roles 
in controlling enzymatic activity, regulating progression through the cell cycle, inducing 
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conformational changes of proteins, and allowing the formation of large protein 
complexes that carry out biological functions and construct highly complex signaling 
networks4. Therefore, studying these dynamic interactions between specific proteins is 
crucial in understanding important aspects of cellular function, and ultimately the 
properties that distinguish between cell types that functionally constitute the whole 
organism. Localization of proteins is one of the mechanisms exploited by cells in the 
dynamic regulation of numerous biological signaling networks5. The precise control of 
protein localization in time and space is vital to cells because mislocalization of a protein 
can prevent it from performing a proper function and impact the entire cellular network6. 
 
Cellular localization of proteins 
Proteins are synthesized in the cytoplasm but they shuttle throughout the cell. 
Many events occur following the protein synthesis including proteolysis, post-
translational modification and protein folding. Briefly, proteolysis is the removal of N-
terminal, C-terminal or internal amino-acid residues. Post-translational modification 
serves as important cell signaling components such as phosphorylation, glycosylation, 
lipidation, and carbonylation. Protein folding is usually required for the natural function 
of the protein. Polypeptide chains often fold to form native secondary and tertiary 
structures.  
Processed proteins are typically transported to a specific location of the cell 
determined by their role and function at a given time throughout the cell cycle, but how 
proteins are targeted to specific organelles or cellular structures remains unclear. A 
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common technique for assessing protein localization is fusing the protein of interest to a 
"reporter" such as green fluorescent protein (GFP) and subsequently expressing it in a 
cell7. Fluorescence microscopy can be used to visualize the fusion protein8. 
 
Roles of proteins in cell signaling and ligand binding 
Biological processes can involve hundreds of proteins, especially cellular 
responses and signal transduction. Some proteins, such as insulin, are extracellular 
proteins that are synthesized and transmitted to other cells in distant tissues as a signaling 
molecule. Others are located in the membrane and act as protein receptors, whose main 
function is to bind external stimuli and send a signal to the cell. The biochemical 
responses may be enzymatic activity or a conformational change detected by other 
proteins within the cell9. For example, transmembrane proteins containing internal 
channels serve as ligand transport proteins that allow polar or charged molecules and 
ions, which are difficult to diffuse through the hydrophobic core of the membrane, enter 
or exit the cell.  
As an example of a highly complex regulatory network, the interactive map of 
E2F1 is illustrated (Figure 1.1)10. E2F1 is a transcription factor, whose deregulation has 
been involved in cancer progression, invasiveness, metastasis, and resistance to anti-
cancer drugs10. This is simply one example of a remarkable protein family that interacts 
with many genes, proteins, and other transcription factors through a vast array of 
mechanisms that link essential cancer-related cellular processes such as proliferation, 
apoptosis, and differentiation. Although this protein and pathway have been extensively 
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studied, a number of other proteins and signaling networks remain unclear. The crosstalk 
between the entire cell signaling network in both normal cells and cancerous cells is still 
poorly understood10. One way to dissect this complicated interaction network is to 
perturb the system at the biologically-relevant scales. This prompts scientists to develop a 
variety of research tools and techniques to study protein-protein interactions both in vitro 
and in vivo using molecular, genetic, or chemical approaches11-12. In recent years, 
progress has been made towards understanding and elucidating protein-protein 
interactions in living systems. Thus, many different techniques have been invented to 
experimentally control protein-protein interactions in living organisms13,14. One of the 
most powerful techniques relying on the use of small molecules is chemically-induced 

































Figure 1.1 | An example of a modularized map of E2F1 in tumor progression and 


























































































































Controlling protein-protein interactions to probe their biological function using 
chemical inducers of protein dimerization in living cells 
As mentioned previously, protein-protein interactions play a vital role in cellular 
processes ranging from cell division, migration, to death. To probe their function, a 
powerful technique is to perturb or conditionally control protein interactions with 
timescales comparable to those that actually occur in living cells. Such timescales would 
allow for the observation of changes in the cell and the formation of hypotheses and 
assumptions regarding a given protein’s interaction network.  
Chemically-induced dimerization (CID) technique15-16 harnesses the naturally-
occurring property of proteins that bind small-molecules to control protein-protein 
interactions using ligands. This technique has opened up new avenues to study complex 
biological networks, and has led to the development of a new field of chemical biology in 
which the use of small molecules is employed to elucidate biology17. The principle of the 
CID technique is conceptually straight-forward: two proteins that require a small 
molecule in order to interact with one another are brought together upon addition of a 
ligand that can simultaneously bind both proteins. The spatial proximity induced by the 
ligand can sway the two proteins to interact in some way, resulting in biological effects 
(Figure 1.2). When two copies of the same protein are dimerized or oligomerized, the 
process is called “homodimerization” (Figure 1.2A). Conversely, if two different 
proteins interact, the term “heterodimerization” is employed (Figure 1.2B). Throughout 
my thesis, I will frequently use the term “dimerization”, which could be ambiguous, but 
in most cases, it will refer to “heterodimerization” of different proteins as this is the focus 
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of our research. In the past three decades, scientists have created new dimerization 
platforms as research tools; a well-known example being rapamycin-induced 
dimerization system18,19. With the power of recombinant DNA technology, proteins of 
interest can be genetically tagged with these dimerizing domains, enabling the study of 































Figure 1.2 | Schematic diagrams illustrating the basic principles of chemically-inducible 
dimerization (CID). Dimerization is triggered by the addition of a small molecule. (A) 
Homodimerization of two copies of the same protein. (B) Heterodimerization of two different 
proteins. (C) CID can be employed as general technique to induce protein‒protein interactions by 
proximity effects, and consequently activate biological phenomena. Using protein engineering 
technique, any proteins of interest to be dimerized can be genetically fused to a pair of 








Brief history of chemically-induced dimerization (CID) 
In 1993, a seminal work16 led by Schreiber and Cabtree reported the novel 
synthetic dimeric ligands, FK1012 derivatives, based on a natural product, FK506 
(Scheme 1.1)16. These synthetic ligands were used to induce homodimerization of a 
protein, artificially triggering T-cell receptor (TCR) signaling pathway in the absence of 
any native TCR ligand. The oligomerization of the intracellular signaling domain of TCR 
lacking its transmembrane and extracellular domains is elegantly demonstrated as the 
first example. This work was initially inspired by the studies on the mechanism of action 
of immunosuppressants, FK506, rapamycin, and cyclosporin A (CsA). They showed that 
these synthetic ligands acted as natural ligands to dimerize the protein target, calcineurin 
for CsA-cyclophilin and FK506-FKBP complexes. As a result, the dimerization blocked 
the translocation of the cytosolic component of the nuclear factor of activated T cells 
(NF-AT), and ultimately suppressing the activation of the genes necessary for T-cell 
proliferation. Similarly, rapamycin binds the cytosolic protein FK-binding protein 
12 (FKBP12) but the rapamycin-FKBP12 complex inhibits the mammalian target of 
rapamycin (mTOR) pathway by directly binding to mTOR Complex 1 (mTORC1)18. 
Although the seminal work from Schreiber and Cabtree16 showed homodimerization or 
oligomerization of a protein, this first report on using a synthetic ligand as a general 
technique to conditionally control protein interactions could potentially be applied to 
almost any protein of interest. This has also paved the way to the development of the CID 





Scheme 1.1 | The first synthetic small molecule homodimerizer FK1012 and its derivatives. 
(A) FK1012-A was first synthesized by linking two copies of FK50616, the ligand for FKBP (FK506 
binding protein). FK1012 E/Z-3 was later synthesized via a single-step olefin metathesis using 
Grubb’s catalyst, which can be reduced to obtain FK1012H220. FK1012 bind wild-type (wt) FKBP, 
abundantly expressed in many eukaryotes. All FK1012 derivatives have been tested and shown 
to effectively homodimerize FKBP. (B) AP1510 is built from a fully synthetic FKBP ligand (SLF) 
that is structurally simpler than FK506. (C) AP1903 is added a bulky group to SLF, which now 
SLF’ binds specifically to FKBP’ (F36V mutant), homodimerizes the mutant FKBP but not bind 
endogenous FKBP. (D) AP20187, a commercially available homodimerizer with improved 


















Applications of chemically-induced dimerization (CID) 
Beyond the previously mentioned application of CID, numerous biological 
processes have been explored using this technique. Briefly, presented below is an 
overview of how CID can be exploited to direct protein interactions in several scenarios. 
The applications have been categorized into two primary groups: dimerization to control 
specific biochemical reactions or cell signaling pathways and dimerization to control 
protein translocation, the primary focus of our research. 
 
1.1 Dimerization to control specific biochemical reaction and cell signaling pathways 
Controlling protein-protein interactions to induce a specific biochemical activity 
without directly altering cellular localization of targeted proteins was the first application 
of inducible dimerization in the original work from Schreiber and Crabtree16 (Figure 
1.3A). This technique established a general principle of  homodimerization and 
heterodimerization of proteins as a key step to activate signal transduction in many 
different cellular pathways15,16,18,19,21 including autophagy, apoptosis, ER stress, cell 
proliferation, cell migration, intracellular cargo transport, regulated cell cycle, embryo 
developmental, stem cell differentiation, gene expression, protein folding and ER quality 
control, protein degradation, and neurodegenerative disease development and 
progression. Many signaling pathways and networks have been systematically studied 
and dissected in broader contexts leading to new discoveries and treatments of diseases. 
This technique can even be used for therapeutic applications in cancer treatments such as 
the first-ever approved gene therapy (CAR-T)22-24 and the promising cancer-targeted 
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protein degradation25-27. Very recently, chimeric antigen T cell receptors (CAR-T) 
immunotherapy has been approved by the US Food and Drug Administration (FDA) for 
the use against acute lymphoblastic leukaemia (ALL) in children whose cancer is 
resistant to most drugs available23,24. The principle behind this technique is T cells are 
drawn from a patient and engineered receptors specific for the patient's particular cancer 
are expressed onto the T cells by transferring the coding sequence utilizing retroviral 
vectors. These modified T-cells are then reintroduced into the patient, they specifically 
recognize cancerous cells, and began killing them effectively. Unlike antibodies against 
tumor-associated antigens, these CAR-T cells, are not quickly cleared by the body; 
fortunately, prolonged exposure to CAR-Ts is necessary for good clinical outcome28. 
However, a significant side-effect is cytokine storm release due to CAR-T cell 
cytotoxicity against normal cells that express the same receptor, as cancer even with low 
abundance can cause multi-organ failure and death. A promising way to circumvent this 
problem is introducing an inducible suicide gene activation with a drug to achieve a 
remote control, simply called an “OFF-switch” of T-cell activity, which is under clinical 
investigation28. CID has also been adopted for a similar purpose using a rapamycin-
inducible dimerization by designing and incorporating an “ON-switch” CARs that enable 
small molecule-induced assembly of the split receptors (inactive forms)29. T cell 
functions are only activated in the presence of a rapamycin analogue that dimerizes the 
receptor to regain its function while still retaining antigen specificity29. This allows 
physicians to fine-tune the timing and dosage of T cell activity, thereby mitigating 
toxicity29.  
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Another biochemical activity that has been successfully made inducible using 
CID technique is split proteins21,30. Exploiting the technique of protein fragment 
complementation, two separated non-functional parts of a protein can be reconstituted to 
restore the full activity of the intact form. Previously mentioned signaling responses 
involving enzymatic reactions i.e. kinases and caspases, which are naturally activated by 
dimerization and oligomerization. In contrast, inteins and proteases are normally active as 
monomers, but when they are split into two separated fragments, they are no longer 
active31,32. Proteins with distinct functional domains, e.g. glycosyltransferases have been 
shown to be non-functional when split into a golgi-targeting domain and a catalytic 
domain33. However, addition of a small-molecule capable of inducing dimerization of 
these domains allows the control of protein glycosylation33. Engineering split proteins 
with a single-domain globular structures can be challenging because the absence of 
essential amino acids can dramatically affect the protein folding. However, some success 
has been acheived as shown with β-lactamase, β-galactosidase, DHFR, GFP, firefly 
luciferase, ubiquitin, dnaE intein and TEV protease30.  
 DnaE intein and TEV protease are worth emphasizing because they are proteins 
that can catalyze ligation and cleavage of protein substrates, respectively. Upon 
dimerization of the split DnaE intein fragments, of which each is fused to a split protein 
of interest, protein ligation and splicing occurs. The protein of interest is reformed, exiled 
from the intein domains, resulting in traceless dissociation from the dimerization 
domains. This could be advantageous when a protein of interest is sensitive to protein 
fusion32,34. A major drawback is that the process is inherently irreversible. Likewise, TEV 
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is a highly specific cysteine protease from Tobacco Etch Virus (TEV), recognizing and 
cleaving a sequence that can be genetically incorporated into a protein of interest. The 









































Figure 1.3 | Inducible protein dimerization to control a biological process. (A) Dimerization to 
induce a specific biochemical reaction without changing localization of proteins. An intrinsically 
localized protein of interest (POI) or different target proteins (POI1 and POI2) can be fused to 
dimerization domains (DDs). Addition of a ligand dimerizer activates a signaling pathway. (B) A 
pathway triggered by interactions between an intrinsically localized protein (POI1) and a 
cytoplasmic, freely diffusible protein (POI2) can be activated by recruiting POI2 to a target in a 
cellular compartment, increasing the local concentration of a protein. (C) A pathway, which is driven 
	 18 
by localization of a freely diffusible protein (POI2) at a subcellular location or triggered by 
interactions with an intrinsically localized protein (POI1), can be silenced by recruiting the diffusive 
protein to another location, where it cannot interact with its partner or perform its function. 
 
1.2. Dimerization to control protein translocation 
Inducible protein translocation is a technique using chemically-induced 
dimerization to change localization of a protein of interest18. In the previous applications, 
biological effects are induced by increasing the effective concentration of two proteins, 
without necessarily altering their localization. In contrast, CID has been used to 
effectively control the localization of proteins by recruiting a protein of interest to the 
desired location (Figure 1.3B). This can be achieved by fusing a dimerization domain to 
a protein that is known to localize to the desired location and a protein of interest fused to 
another dimerization domain. Although the protein of interest may be diffused throughout 
the cell or naturally reside in a different compartment, the protein of interest must travel 
outside its native location to interact with the recruiter. The equilibrium will eventually 
shift toward the low energy state to form a dimerization complex at the desired location, 
depleting the protein of interest from its original site (Figure 1.3B). CID has been 
successfully applied in recruiting proteins to different cellular compartments such as the 
plasma membrane, mitochondria, peroxisomes, the nucleus, specific genomic loci18. 
Recently, our lab has demonstrated that the recruitment of a cytoplasmic protein to 
centrosomes, centromeres, and kinetochores (Chapter 2). CID offers several advantages 
over genetically fusing a protein of interest directly to a localizable motif, primarily 
temporal and, in some cases, spatial control. Spatiotemporal control is important for 
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studying protein interactions and localization on subcellular levels with time resolution 
similar to natural processes.  
Inducible protein translocation can be used to turn on or off a biological process 
by either recruiting a protein to or removing it from the location in which it is normally 
active (Figure 1.3B and C). Many cellular events are tightly regulated via the access of 
signaling proteins to a specific location such as the plasma membrane, to interact with 
other proteins. Conditionally controlling the access of proteins has been used to activate 
or inactivate biological processes with the plasma membrane being a common target for 
inducible protein translocation. The first example of inducible protein relocalization to 
turn on a pathway is the recruitment of Src kinase to the plasma membrane, which was 
shown to be sufficient to activate Src signaling cascades16. Heterotrimeric G proteins37,38 
and the kinases and phosphatases involved in phospholipid signaling39-41 have been 
extensively studied using CID as a protein translocation tool. My colleague, Dr. Ballister 
exploited this technique to temporally induce the localization of a spindle assembly 
checkpoint protein, Mad1, at kinetochores42. He elegantly showed that recruitment of 
Mad1 to kinetochores is sufficient to reactivate the mitotic checkpoint even after it has 
been silenced through the normal cell cycle, demonstrating the power of CID as a protein 
translocation technique42. 
Inducible translocation, on the other hand, can also be used to inhibit a protein 
function by sequestering it in a location that it is inactive (Figure 1.3C). The idea is 
similar to the nuclear import or export process in which proteins are only active in the 
designated location of the cell. A target protein can be sequestered from its functional site 
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through inducible dimerization using nuclear import or export as an anchor for a 
dimerization domain43-46. This translocation could potentially be useful to probe protein 
function with a technique called “knock-sideways”46-49. 
 
Chemical dimerizers developed to date 
Numerous applications of CID, particularly rapamycin-inducible systems, have 
proven to be tremendously useful for research in biomedical science, and have been 
crucial in significantly advancing the field over the past decades. Since the introduction 
of FK1012 as the first chemical inducer of protein homodimerization, a variety of 
different homodimerizers have been developed and utilized for biological applications. 
Some are natural product-based homodimerizers such as cyclosporin-A (CsA2)50-51, 
Coumermycin52-53; others are fully synthetic such as a series of symmetric 
homobifunctional O6-benzylguanine (BG) molecules (termed CoDis)54 and xCrAsH55. As 
mentioned previously, the focus of this work is on heterodimerization as opposed to 
homodimerization, as reflected in my effort to develop a new series of heterodimerizers. 
 
Chemical inducers of protein heterodimerization 
 For chemical inducers of protein heterodimerization, rapamycin and its analogs 
are undoubtedly the most widely used chemical heterodimerizers (Figure 1.4A)18. 
Rapamycin (Sirolimus) is a macrolide compound, first isolated from the bacterium 
Streptomyces hygroscopicus, found on Rapa Nui (Easter Island).  It was first reported as 
an antifungal drug but soon later was discovered that rapamycin also	 has potent 
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immunosuppressive and anti-proliferative properties56. The mechanism of action is as 
follows: rapamycin first binds FKBP, forming a rapamycin-FKBP complex to which the 
kinase Target of Rapamycin (TOR in yeast, mTOR in mammals) can only bind57-61. 
Rapamycin sequentially binds FKBP and mTOR (or a small fragment of mTOR called 
FRB) (Figure 1.4B) with nanomolar affinity62-63. This sequential binding mechanism is 
highly advantageous as it prevents the “hook effect”, when two separate dimerizer 
molecules simultaneously saturate the binding sites of each protein, blocking the 
formation of ternary complex. For a deeper illustration of this effect, please refer to the 
final section of this chapter. As rapamycin rapidly passes the cell membrane and 
cooperatively binds its target proteins FKBP and FRB with high affinity, it quickly 
became a popular platform and was used as a general tool for heterodimerization of 
FKBP and FRB fusion proteins since 199664,65. Since FRB only binds to the pre-bound 
FKBP-rapamycin complex, high concentrations of rapamycin can be added to cells in 
order to drive the rapid intracellular flux and dimerization42. However, there are still four 
major limitations to rapamycin. First, its interference with mTOR signaling as a potent 
inhibitor of mTOR, producing significant off-target effects. Second, rapamycin can 
competitively bind with endogenous FKBP, preventing the dimerization with FKBP-FRB 
tagged protein of interest. Third, spatial control over dimerization on a single-cell and 
subcellular levels cannot be achieved using rapamycin system.  Lastly, studying the effect 
after reversal of the dimerization on biologically-relevant short timescales is nearly 
impossible due to the inherently tight binding ternary complex. Due to rapamycin being 
one of the first chemical heterodimerizers developed more than two decades ago, 
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rapamycin-based systems have been in the spotlight, leading to extensive modifications 
















Figure 1.4 | Chemical heterodimerizers with sequential binding mechanisms. (A) chemical 
structures of FK506, Rapamycin, and AP21967. Binding surfaces are highlighted. (B) Rapamycin 
first form a complex with FKBP, which then binds FRB (or mTOR). All three components contact 
each other in this ternary complex. (C) Bump-and-hole technique is used for the design of 





To address the first problem with off-target effects, rapamycin analogs have been 
developed using the “bump and hole” technique. A bulky group (bump) is added to the 
rapamycin structure on the FRB binding surface to create an analog that binds selectively 
to a mutant FRB with a larger rapamycin binding pocket (hole). The “bump” prevents the 
rapamycin analog from binding endogenous mTOR (Figure 1.4C)66. The most widely 
used rapamycin analog (rapalog) (AP21967, Figure 1.4A), is commercially available. 
Unfortunately, the second problem with competitive binding to endogenous FKBP, has 
not been widely addressed. No rapalogs that are selective for a mutant FKBP have been 
reported. Thus, high levels of exogenous FKBP and FRB fusion protein expression are 
necessary to achieve high efficiency of the dimerization. This limitation can also be 
effectively overcome by deleting or depleting endogenous FKBP42 although this can 
create another problem with a knock-out or knock-down effects in some cases. Finally, 
the reversibility and lack of spatial control over dimerization issues of rapamycin-based 
systems have been addressed by a variety of techniques such as using an analog with a 
weaker binding affinity (a synthetic ligand of FKBP or SLF), which can be displaced by 
the addition of rapamycin18. Alternatively, the development of completely new 
dimerizers to overcome these issues has been an active area of research of many 
laboratories, including our lab.  
 
Development of new chemical dimerizers 
The profound limitations of rapamycin and promising future of this technique as 
an emerging tool for biologists has led to new avenues of research in chemical biology. 
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With collaboration between synthetic chemists and biologists, these issues can be 
overcome by the development of new molecules that fulfill the requirements of being “a 
good dimerizer” for mammalian cell studies. 
A “good dimerizer” has several distinct characteristics. An ideal chemical 
dimerizer would rapidly enter cells and bind to its target proteins with high specificity, 
forming a stable ternary complex for a reasonable length of time. The dimerizer cannot 
be cytotoxic to cells or interfere with other biological pathways. One strategy to increase 
the “bioorthogonality” of dimerizers is to use systems from other species such as bacteria 
or plants as they do not have targets in mammalian cells.  
For this review, specific examples (summarized in Table 1.1) from the literature 
to illustrate have been selected to illustrate a variety of the new dimerizer developments 
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The first generalizable chemical inducer for protein heterodimerization is FK506 
(Figure 1.5A), developed in 1996. FK506 by itself could theoretically be used as a 
heterodimerizer, inducing FKBP and calcineurin A (CnA) dimerization64. Since then, 
FK506 has been conjugated with other small molecules such as Cyclosporin-A to 
generate FK-CsA (Figure 1.5A), the first artificial semi-synthetic heterodimerizer. FK-
CsA dimerizes FKBP and Cyclophilin A fusion proteins67. By coupling FK506 to a 
glucocorticoid hormone analog, dexamethasone, Dex-FK506 (Figure 1.5B) was 
synthesized and used to induce dimerization of wild-type FKBP and the full-length 
glucocorticoid receptor (GR) fusion proteins68. FK506 was used again by Schrieber’s lab 
to produce FK506-FK506 derivative, dimerizing FKBP and mCAB (fusion of CnA340-
394 and CnB3-170 with specific mutations)71. However, FK506-based dimerizers still 
competitively bind endogenous FKBP12 limiting their efficiency and applicability. 
Rapamycin and its analogs were introduced in 1996 and 1997, and have shown to be 
more promising than FK506 although they still have some serious limitations as 
previously mentioned. A few years after FK506 and rapamycin dimerizers were reported, 
Virginia Cornish’s lab has pioneered the development of new systems, aiming to 
overcome some limitations of existing dimerizers. Several dimerizers, composed of 
ligands for steroid receptors (hormone binding domain of GR) and dihydrofolate 
reductases (DHFRs) were produced from either commercially available materials or 
simple synthetic strategies. The first dimerizer from her lab, developed in 2000, was Dex-
Mtx (Figure 1.5C) which combines dexamethasone with methotrexate (Mtx), a 
dihydrofolate reductase (DHFR) inhibitor that binds both DHFRs from bacteria and 
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eukaryotes with low selectivity70. The Cornish lab later in 2007 developed another 
dimerizer, Dex-TMP (Figure 1.5E), which the Mtx ligand was replaced by trimethoprim 
(TMP), an inhibitor 1000-fold more selective toward bacterial vs mammalian DHFRs73. 
Dex-TMP solves the issue observed with Mtx, namely the non-selective binding to 
mammalian DHFR, but it may still have some undesirable off-target effects from 
dexamethasone inhibitory activity. Historically, Dex has been prescribed as a 
corticosteroid drug81 for a variety of treatments including rheumatic problems, skin 
diseases, severe allergies, asthma, chronic obstructive lung disease, croup, brain swelling, 
and tuberculosis. Corticosteroids or steroid hormones are involved in a wide range of 
physiological processes including stress response, immune response, regulation of 
inflammation, carbohydrate metabolism, protein catabolism, blood electrolyte levels, and 
behavior in humans. Some severe adverse effects may occur81. 
Back in 2003, Kai Johnsson’s lab reported a new heterodimerizer, utilizing 
methotrexate (Mtx) and his newly developed covalent protein labeling system called 
SNAP-tag. He combined the SNAP-tag ligand, O6-benzylguanine (BG) with Mtx, 
creating the first half-covalent dimerizer, BG-Mtx (Figure 1.5D)72. This molecule forms 
a covalent attachment with the SNAP-tag protein, an engineered human O6-alkylguanine-
DNA alkyltransferase (hAGT), but forms a non-covalent interaction with DHFR. 
Although these modular dimerizers have been successfully applied to induce protein 
dimerization in living cells, the concentration of the dimerizer must be carefully 
controlled. Excess dimerizer molecules can cause non-cooperative or non-productive 
binding, preventing the ternary complex formation (the hook effect). One of the 
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advantages of a half-covalent dimerizer like Mtx-BG is the unreacted or excess dimerizer 
can be washed out, improving the dimerization efficiency. However, the wash-out 
effectiveness must still be carefully examined for every different dimerization system and 
experiment. In theory, this modular half-covalent design is far superior compared to 
completely non-covalent systems, prompting us to adopt this strategy in our new 
dimerizer design. 
In 2008 Carolyn Bertozzi’s lab, in collaboration with the Cornish lab, reported 
TMP-SLF (Figure 1.5F), a dimerizer containing a synthetic ligand of FKBP (SLF) 
combined with TMP33. SLF is an analog of FK506 that lacks the ability to inhibit 
calcineurin but still binds tightly to FKBP, meaning competitive binding to endogenous 
FKBP is still an issue.  
 Notably, in 2011 and 2012, two completely new chemical dimerizers based on 
plant hormones and their natural receptors, Abscisic acid (ABA) and Gibberellin (GA) or 
specifically Gibberellic acid (GA3) were reported (Figure 1.5G)74,75. These plant 
hormones exhibit a similar sequential binding mode to rapamycin in that they initially 
bind the first receptor and the resulting binary complex then binds the second protein, 
preventing the hook effect. The difference is in the initial binding event, as the plant 
hormones induce a dramatic conformational change of the protein receptor in order to 
bind the second target (Figure 1.6B)82,83. ABA dimerizes its receptor, pyrabactin 
resistance(PYR)/PYR1-like (PYL) and a protein phosphatase PP2C, whereas GA3 binds 
the receptor gibberellin insensitive dwarf 1 (GID1) and another protein called gibberellin 
insensitive (GAI). Both ABA and GA3 are non-toxic at concentrations used and were 
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successfully applied to control signal transduction and protein translocation in living 
mammalian cells74,75. However, optimization of the systems was required as both 
molecules contain a carboxylic acid group that is deprotonated and negatively charged at 
physiological pH; this characteristic is known to hamper cellular permeability, 
necessitating high micromolar concentrations of ABA, and a long incubation period (~30 
min). Cleverly, Miyamoto and coworkers tackled this limitation by masking the 
carboxylic acid group of GA3 with an ester protecting group (acetoxymethyl, or AM) to 
yield a neutral prodrug dimerizer, GA3-AM that is more readily cell-permeable (Figure 










Figure 1.6 | The plant hormones Absciscic Acid (ABA) and Gibberellin 3 (Gibberellic Acid 3 
or GA3). (A) GA3-AM is a prodrug form of GA3 in which the carboxylic acid group is masked as 
acetoxymethyl ester. This modification significantly improves cellular permeability because once 
inside the cell, the masking group is rapidly removed by promiscuous esterases, yielding GA3. (B) 
These plant hormones confer a sequential binding mechanism of protein dimerization, similar to 
that of rapamycin, but it differs in the structural basis. Like rapamycin, ABA and GA do not bind 
the secondary receptor by themselves, but rather initially bind the first hormone receptor, and 
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then this complex binds a secondary receptor. In contrast to FK506 or rapamycin, ABA and GA 
binding induces structural rearrangements of the primary receptors, allowing the binding to the 




promiscuous intracellular esterases (Figure 1.6A), allowing maximal GA3-induced 
dimerization within 60 seconds. The slow cellular uptake of ABA could be significantly 
improved by the same prodrug strategy, but it has never been reported. Unfortunately, 
none of the new dimerizers reported so far have shown faster kinetics of dimerization 
compared to rapamycin-based systems (~10 seconds)42. Although ABA and GA3-AM are 
not yet commercially available, these new dimerizers are promising for future 
applications due to their cooperative binding mechanism, similar to rapamycin but have 
no targets in mammalian cells. Moreover, due to the orthogonality of GA3 to previously 
developed systems it has been used in conjunction with rapamycin to construct AND and 
OR logic gates using cell morphology changes (membrane ruffling) as the phenotypic 
output signal. This has opened up new possibilities in the areas of CID and synthetic 
biology. Unfortunately, some limitations of these molecules are the lack of spatially-
controlled induced dimerization and reversibility on biologically-relevant timescales.  
 In 2013 Fusicoccin (FC), a natural product produced by the fungus Fusicoccum 
amygdali, was reported as a chemical dimerizer (Figure 1.5G). It dimerizes an 
engineered 14-3-3 protein and the C-terminus (CT) of the proton ATPase fusion protein. 
Although this dimerizer was reversible and claimed to exhibit a cooperative dimerization 
event76,84, it did not receive much attention. Perhaps because 14-3-3 proteins are a family 
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of regulatory molecules conserved in eukaryotes, binding to functionally diverse 
signaling proteins, this relatively new and complex system requires additional 
characterization and optimization for increased adoption. Nonetheless, this orthogonal 
system expands the CID toolbox and is complementary to existing systems. 
 In the same year, Matthias Wymann’s lab reported a novel CID system employing 
two covalent ligands from protein labeling methods, Halotag and SNAP-tag (Figure 
1.5H). A series of covalent heterodimerizers were developed as a general form, Halo-X-
Snap (Figure 1.5H), where X refers to various linkers77. They demonstrated that the 
linker can contribute to cell permeability and overall efficiency of dimerizer. The most 
optimal molecule (HaXS8, Figure 1.5H) showed the highest level of dimerization (65% 
of total protein) with the fastest kinetics (>15 minutes). Nonproductive binding was 
observed when excess dimerizer was used. Slow kinetics, lack of spatial control and 
irreversibility are the major limitations. The same group later inserted a photocleavable 
linker into this dimerizer (MeNV-HaXS)85 and demonstrated a light-controlled release of 
a protein from individual vesicles. Using light to reverse the dimerization with 
spatiotemporal control on a subcellular scale is a powerful solution to solve several 
limitations of previous dimerizers. Thus, this has inspired us to develop our own 
photocleavable dimerizers (Chapter 3 and Chapter 4). 
 2014 held significant advancements for the CID field, three new heterodimerizers 
were developed and reported including our first generation dimerizer (Chapter 2). Carsten 
Schultz’s lab published a new dimerizer rCD178 (Figure 1.5I), comprising of BG (SNAP-
tag ligand) and SLF, and used it with FK506 as a way to reverse dimerization78. There 
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seemed to be a common problem with the BG ligand-containing dimerizers, which is 
slow kinetics of either cellular uptake or the labeling reaction with the SNAP protein 
(>30 min to achieve the maximal dimerization after addition). Interestingly, upon 
addition of FK506 the dimerization could be rapidly reversed within a minute. A few 
months later, Yao-Wen Wu’s lab reported another dimerizer consisting of SLF’ (a 
synthetic ligand of F36V mutant of FKBP (referred to as FKBP’), and TMP (Figure 
1.5J)79. SLF’ binds the FKBP’ with sub-nanomolar affinity and displays a 1000-fold 
selectivity for this mutant over the wild-type FKBP, thus minimizing the off-target 
effects and endogenous FKBP interference. In addition to the advantages of using TMP 
as mentioned previously, the non-covalent nature of the interaction allows dimerization to 
be reversible with competitive binding of the original TMP drug. This reversibility with 
TMP can be multiple times before rapamycin can be added to permanently reverse the 
dimerization. The group used this dimerizer to reversibly induce lamellipodia formation 
in living cells. Beyond this, they considered the applicability of the dimerizer for double 
relocation of proteins by adding rapamycin, rerouting a protein from the membrane to 
mitochondria with fast kinetics79. This dimerizer highlights the advance of CID in terms 
of cycled reversibility that was previously impossible with dimerizers such as GA3 and 
rCD1. Some drawbacks, however, include the lack of spatial control over dimerization 
and reversal when using rapamycin, which is probably not the best option due to its off-
target effects. Optimal concentrations of TMP-SLF’ need to be determined for a given 
experiment due to its non-cooperative binding mechanism. Overall, TMP-SLF’ will 
likely become one of the most promising dimerizers for future applications in biology 
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communities once it is commercially available or more readily accessible. The complex 
synthesis of SLF’ is a significant barrier, preventing it from becoming popular. In 
addition, we also reported another TMP-based dimerizer (chapter 2) that is coupled to 
Halotag system in the same year (Figure 1.5K)80. 
 In summary, no dimerizer is perfect as each possesses varying strengths and 
weaknesses depending on the application. Some major limitations of these dimerizers, or 
the CID technique, in general, are that most of them are irreversible on the biologically 
relevant timescales or they lack spatial control over the reversibility on single-cell and 
subcellular levels. This limits their potential to dissect highly dynamic and reversible 
biological events or complex cell signaling networks, with comparable precision 
analogous to natural processes.  
To combat these issues, a powerful approach is the use of light as an external 
stimulus to activate small molecules or protein‒protein interactions. Light can be applied 
to a specific region within a cell through well-developed optical microscopy techniques. 
With its “on-demand” feature, optical control of molecules enables high spatiotemporal 
precision. A promising strategy to create light-inducible CID systems is photocaging86,87. 
A molecule is masked, or “caged” by a photoremovable protecting group resulting in the 
silence of the molecule’s function88. Illumination removes the cage and restores its 
function. Photocaging biomolecules has been around for decades with widely used 
biomolecules including signaling messengers such as caged-glutamate, caged-adenosine-
triphosphate (ATP), and caged amino acids such as lysine. Optically controlling protein 
function by blocking the reactive amino acid residues with a photolabile protecting group 
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can prevent the protein from performing catalytic event or interacting with other proteins. 
Photocaged CID of proteins have been reported to allow light-triggered dimerization with 
spatiotemporal control; we are particularly interested in exploiting this strategy in our 
research. 
Prior to the discussion of photocaged dimerizers, the relevant techniques that also 
harness light as an external stimulus to induce protein-protein interactions or dimerization 
should be explored89-91. These techniques include chemical photoswitches92,93 and 
naturally light-sensitive proteins, also known as optogenetics94,95. Each technique offers a 
distinct set of advantages and disadvantages outlined below. 
 
Light-controlled tools for biology 
Light has been extensively employed as an external stimulus to activate biological 
phenomena89. The ability to regulate proteins or signaling molecules, which bind and 
activate proteins function, with light provides high spatial and temporal control. There are 
three techniques harnessing the power light to manipulate biological processes; 
photoswitches, optogenetics, and photocaged dimerizers. This work will primarily focus 
on photocaged chemical dimerizers, but also briefly discuss photoswitches and 
optogenetics. 
Chemical photoswitches 
Photoswitches represent a class of molecules that can be switched between at least 
two distinct thermodinamically stable forms in response to the application of light in a 
processed called photoisomerization. A popular example is azobenzene, which is 
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composed of two phenyl rings connected by a N=N double bond (Figure 1.7). It is the 
simplest structure of an aryl azo compound, a term often used to refer to a class of 
molecules that share the same azobenzene core structure with various functional groups 




Figure 1.7 | Reversible photoisomerization of azobenzene 
 
The photoisomerization of trans and cis isomers of azobenzene and its derivatives 
can be induced by particular wavelengths of light. The ultraviolet light (UV) absorption 
corresponds to the of π-π* (S2 state) transition energy gap for trans-to-cis conversion, 
and blue light absorption corresponds to that of the n-π* (S1 state) transition, for cis-to-
trans isomerization. The cis isomer is less stable due to its distorted configuration that is 
less delocalized than the trans configuration. Thus, cis-azobenzene may thermally relax 
in the dark, to the trans isomer although this process is slow at room temperature. Dirk 
Trauner’s lab pioneered research in the area of photopharmacology93, where he uses 
synthetic photoswitches to control biological events. Applications in biology of most 
synthetic photoswitches have been focused on controlling voltage-gated and ligand-gated 
ion channels, resulting in artificial photoreceptors that can be used to optically control 
neurons with exceptional temporal and spatial precision. The technique has been shown 
to work well in animals and is potentially applicable to vison restoration96,97, as well as 
trans-azobenzene cis-azobenzene 
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other sensations. The combination of synthetic photoswitches and receptor proteins 
significantly contributes to the field of optogenetics and adds a new functional dimension 
to chemical genetics, and as such they coined the term “optochemical genetics”93. Using 
this technique, light-induced protein‒protein interactions can be switched on and off “on-
demand”. Although repeated cycles of activation are desired in some applications, intense 
and continuous illumination may be necessary to drive the equilibrium toward the 
activated conformation. Consequently, it may not be an ideal technique to be used for 
applications in which sustained and long-termed dimerization is required. 
 
Optogenetics 
Optogenetics is a technique that uses a combination of optical and genetic 
technique to control and monitor the activities of living cells that have been genetically 
modified to express light-responsive proteins such as ion channels. Initially, after an 
approach involving microbial opsin genes was introduced in 2005, optogenetics has been 
widely applied as a research tool to precisely measure the effects dependent upon the 
manipulation of neurons in a spatiotemporal and specific manner provided by light. In 
2010, optogenetics was selected to be the "Method of the Year"98,99 across all fields of 
science and engineering by Nature Methods, an interdisciplinary research journal. 
Optogenetics was also highlighted in the article on "Breakthroughs of the Decade"100 in 
the academic research journal Science. The optogenetic toolkit has proven to be an 
increasingly important technique in the field of neuroscience. This technique has been 
applied to probe a variety of proteins and cellular functions, extending its scope outside 
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of neurons. Manipulation of contractile forces relevant to cell migration, cell division, 
and wound healing have been demonstrated using optogenetic approaches101. The field is 
rapidly growing and there is a potential to utilize optogenetics in cell and developmental 
biology to dissect signaling pathways by controlling protein localization, post-
translational modification, and GTP loading95. 
 Recently, an emerging application of this technique is reversible and 
spatiotemporal control of protein‒protein interactions via naturally photosensitive 
domains in a similar to CID. Since 2009, there have been four common systems reported 
for light-inducible dimerization: PhyB-Pif (phytochrome B-phytochrome interacting 
factor)102, FKF1-GI (FKF1 and GIGANTEA proteins from Arabidopsis thaliana103, 
Cry2-CIB1 (cryptochrome 2 and its interacting partner CIB1)104 and TULIPs (tunable 
light-inducible dimerization tags) based of LOV2 domain of Avena sativa phototropin 1 
(AsLOV2) and an engineered PDZ domain, ePDZ105. Conceptually, all four systems 
work in the same way: a photosensitive protein (which may or may not contain a 
photosensitive cofactor) undergoes a conformational change in response to light, which 
then allows dimerization with a second (non-photosensitive) protein. The dimerization 
can be reversed in the dark or upon exposure of a different wavelength of light. 
Depending on the system, the dissociation kinetics range from seconds to hours. The 
detailed characteristics of these systems have been reviewed elsewhere94,95. Like 
photoswitches, the main feature of this technique is the repeatability of reversible 
activation-inactivation of protein dimerization. Thus, it is especially suitable for 
controlling biological processes requiring multiple ON/OFF cycles. However, the 
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reversible control may rely on relaxation kinetics in the dark; one has to carefully 
consider what system is most suitable for a particular application. The equilibrium of 
light and dark states may result in “leakiness” of the system where dimerization occurs in 
the dark106,107. Although only Phy/Pif can behave as a rapid on-demand photoswitch 
that is sensitive to red light (650 nm) and far -red light (750 nm), Phy protein itself is 
large (908 amino acids) compared to typical protein tags like GFP (238 amino 
acids).  This bulky tag may be difficult to incorporate or  disruptive when fused to 
proteins of interest. Technical challenges such as gene cloning or  in vitro 
transcr iption should be considered when using this system. Recently, beyond the 
application at the plasma membrane in Levskaya’s paper 102, Phy/Pif dimer ization 
was tested in budding yeast46. Twenty different Phy-tagged fusion proteins that were 
supposed to localize to several distinct compar tments were constructed and 
expressed, but more than half failed to localize proper ly. Notably, all three 
kinetochore targets failed46, indicating that Phy may possess some technical 
challenges to be adopted as a general tool. 
 
Photocaged chemical dimerizers 
 Photocaged compounds are light-sensitive molecules encapsulated in an inactive 
form by blocking an important functional part of the molecule with a photolabile organic 
protecting group. Illumination liberates the caged molecule, permitting targeted 
perturbation of a biological process via protein-ligand interactions. Uncaging technology 
and fluorescence microscopy are two complementary experimental techniques, the 
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former allows photocontrol while the latter allows observation of biomolecules (such as 
proteins) correlating to cellular function. Caged ligands have been applied to a great 
extent in neuroscience; caged glutamate, one of the most popular caged molecules, has 
been very useful for unraveling neural systems. Two-photon cages have enabled the 
stimulation of single synapses in animals with spatial and temporal precision. 
However, some disadvantages associated with caged ligands is that uncaging is an 
irreversible process making it difficult, if not impossible, to turn off the light-activated 
event. Therefore, it is more suitable for studying long-termed effects such as a sustained 
receptor activation or inhibition. In addition, the by-products produced by uncaging such 
as the released protecting group can be toxic to cells. Thermal hydrolysis (in the dark) of 
caged compounds can result in the background release of the ligand. For example, 
neurotransmitters can be problematic as even low concentrations of the neurotransmitter 
can exhibit a signal and contribute to off-target effects. Some of these shortcomings can 
be overcome with the photochromic ligand (PCL) or photoswitchable molecule approach 
as previously described. The ligand carries a photoswitchable moeity that can toggle 
between two states, active and inactive forms. The efficacy of the ligand only changes 
upon illumination, triggering the desired biological effect with light in a reversible 
fashion. Interestingly, the ligand could be an agonist in one form and an antagonist in the 
other. However, to create a general platform applicable in studying diverse proteins, 
photoswitches are not ideal and difficult for biologists to adopt as they require investment 
in the synthesis of new ligands for a specific protein. Hence, CID and optogenetics are 
more appealing in this case. Furthermore, we are interested in studying protein 
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localization, which usually requires prolonged induction of protein-protein interaction, 
but not repeated ON-OFF cycles, making photocaged CID particularly attractive to us.  
For protein heterodimerizers, one of the most investigated molecules is 
rapamycin, which has been caged with many different strategies91,108. For example, a 
commonly used ortho-nitrobenzyl photocage, rapamycin dimer, and biotin conjugated 
molecule. All have been caged at the C-40 hydroxyl group, which is the most chemically 
accessible based on the crystal strucutres, and this hydroxyl group forms hydrogen bonds 
with FKBP.  
Photocaged rapamycin109 was reported using an analog of rapamycin (pRap) and 
an engineered rapamycin binding domain (iFKBP) (Figure 1.8A). Selective acylation of 
the C-40 hydroxyl group with nitro-piperonyloxycarbonyl N-hydroxysuccinimide 
carbonate (NPOCNHS) was utilized as a photolabile protecting group. Inuoe’s lab 
created a biotin-linked rapamycin with a photocleavable linker inserted between both 
ligands (cRb-A, Figure 1.8A)110, a novel photocaging method to spatiotemporally control 
the activity of rapamycin. The rapamycin-biotin molecule was bound to avidin, creating a 
large complex preventing rapamycin from entering the cell. The photocaged rapamycin 
derivative induced rapid dimerization of FKBP and FRB upon UV illumination. With this 
system the spatially confined UV irradiation achieved local activation of Rac, a member 
of small GTPases at a sub-region of the plasma membrane. Although this technique 
offers a powerful approach to studies of dynamic intracellular signaling events, it is 
clearly limited to applications at the plasma membrane due to the cell permeability of the 
dimerizer. Recently, Deiters’ lab reported another derivative, a rapamycin dimer111 with a 
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photocleavable linker (dRap, Figure 1.8A) developed to optically induce FKBP12-FRB 
dimerization only when exposed to light, and successfully applied it to control kinase, 









































Figure 1.8 | Photocaged chemical dimerizers. (A) Photocaged rapamycin structures with 
different approaches. (B) Abscisic acid (ABA) derivatives caged with 4,5-Dimethoxy-2-Nitrobenzyl 
(DMNB) and (7- Diethylaminocoumarin- 4- yl)methyl (DEACM) caging group. (C) Gibberellic acid 
(GA3) derivatives, GA3-1, GA3-2, and GA3-3, caged with 2-(4,5-dimethoxy-2-nitrophe-nyl)propyl 
(DMNPP), (2-(4’-bis((2-methoxyethoxy)ethyl)amino)-4-nitro-[1,1’-biphenyl]-3-yl)propan-1-ol) (EANBP), 
and π-extended 2-(o-nitro-phenyl)propyl caging group, respectively.  
	
lmax = 365 nm lmax = 400 nm lmax = 400 nm 
lmax = 365 nm lmax = 405 nm 
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Other caged dimerizers have been also reported such as ABA and GA3, plant 
hormone-based systems. Abscisic acid (ABA) was chemically modified with a 
photocaging group (DMNB and DEACM, Figure 1.8B) allowing light-induced protein 
dimerization of ABA receptors, ABI and PYL112. They successfully showed dose-
dependent light regulation of cellular processes including transcription, protein 
translocation, signal transduction, and cytoskeletal remodeling, without the need to 
perform extensive protein engineering. Caged ABA can be easily prepared from several 
synthesis steps. Photocaged GA3 derivatives (Figure 1.8C) were introduced as a novel 
one- and two-photon light-activated dimerization system for GID1-GAI fusion 
proteins113. GA3-2 and GA3-3 are sensitive to wavelength at 800 nm due to the EANBP 
photocage. A newly developed compound reported in this paper, a π-extended 2-(o-nitro-
phenyl)propyl caging group, displays red shifted absorption. Interestingly, both ABA and 
GA3 were caged on the carboxylic moiety to form an ester bond which can potentially be 
cleaved by intracellular esterases. The uncaging reaction in the dark should be carefully 
tested in cells to confirm that uncaging event is not from esterases but exclusively occurs 
by illumination. Nonetheless, these systems can be used orthogonally with other light-







The Hook effect (prozone effect) 
The prozone effect or the high-dose hook effect is a known phenomenon in assays 
involving three-component or multivalent binding events, e.g. immunoassays114. It was 
discovered that increasing the concentration of antibody does not necessarily increase the 
binding of antigen. On the other hand, after a certain concentration of an antibody, the 
amount of the antibody-antigen complexes decreases, resulting in lower signal output as 
shown in a plot of complex formation or signal readout vs concentration (Figure 1.9A). 
The region of the overly high antibody concentration was named “prozone”115,116. The 
prozone effect results from saturation of the proteins bound to a “linker or bridging” 
molecules, preventing each other for binding partners and, as a result, reducing the 
amount of fully formed ternary complexes. 
In CID, a ligand or a dimerizer serves as a bridging molecule between its 
receptors. The hook effect is only observed with dimerizers that do not possess 
cooperative binding mechanism such as artificial dimerizers composed of two distinct 
ligands joined together by a linker component. The effect is caused by two different 
dimerizer molecules separately reacting with two different protein receptor molecules, 
inhibiting ternary complex formation (Figure 1.9B). The resulting non-productive 
protein-ligand complexes can significantly diminish protein interaction or dimerization 
efficiency. This is well explained in a recent review from Yimon Aye’s lab117 and also 
observed in PROTACs strategy from Craig Crews’s lab118. Furthermore, David Spiegel’s 





















Figure 1.9 | The prozone or hook effect and explanation. (A) A plot of signal readout as a 
function of concentration of an antibody. (B) Schematic illustration of a bifunctional ligand or a 
dimerizer that can simultaneously bind two different protein domains (green: dimerization domain 
1, DD1; orange: dimerization domain 2, DD2). An optimal concentration of the dimerizer efficiently 
induces dimerization of the two proteins. In contrast, excess dimerizer molecules can saturate 
both binding sites, preventing the formation of ternary complex. 
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Motivation to develop our novel system 
In addition to our work (Chapter 2-4), there are only three photocaged dimerizers 
reported to date, rapamycin, ABA, and GA3. As an immunosuppressive drug, rapamycin 
has inherited properties that can interfere with the mammalian mTOR signaling pathway, 
it can competitively bind to endogenous FKBP, reducing the efficiency of the exogenous 
FKBP and FRB dimerization. Photocaged rapamycin derivatives made with MeNPOC 
caging group at C-40 is not totally sufficient to block the interactions of rapamycin and 
FKBP, resulting in leakiness prior to light-activation. Photocaged rapamycin conjugated 
with biotin is not cell-permeable, thus it is limited to only plasma membrane targeting. 
Although photocaged ABA and GA3, plant-based systems, do not have endogenous 
targets in mammalian cells, they are not efficiently cell-permeable and in some cases, 
higher concentrations are required, leading to undesired cytotoxicity. Notably, it has been 
reported that these molecules increased cellular acidity, which may activate off-target 
effects. 
Additionally, none of the above mentioned photocaged dimerizers are covalent 
dimerizers, thus they can diffuse away from the location where they were photoactivated 
after uncaging; i.e. they lack localized target manipulation. Moreover, all the photocaged 
dimerizers reported to date are not based on a modular design resulting in difficulties in 
making structural modifications for fine tuning properties tailored for different purposes 
or improving the system for broader applications in both in cultured cells and other 
popular model organisms such as C. elegans, Drosophila, zebrafish, Xenopus, and mice. 
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These limitations of existing photoactivatable CID systems have prompted us to develop 
a new photocaged dimerizer possessing the following properties: modular design for 
future modifications, high spatiotemporal control, specificity, and cell-permeability, 
sequential binding mechanism to avoid the hook effect, no toxicity, and completely inert 
prior to uncaging and reversible. To accomplished this goal, we have successfully 
synthesized a novel photocaged dimerizer composed of a non-caged covalent ligand and 
a photocaged non-covalent ligand jointed by a simple linker. Our first generation 
photocaged dimerizer exhibits excellent light-inducible dimerization properties that will 
be discussed in Chapter 2. Following this, we developed a second-generation photocaged 
dimerizer more sensitive to light and longer wavelengths as compared to the first 
generation (Chapter 3). The lack of spatial control for the reversal of dimerization and the 
slow reversibility of our previous dimerizers led us to develop a photocleavable dimerizer 
based on the same platform (Chapter 3). This photocleavable dimerizer exhibits rapid 
light-induced reversal of dimerization with high spatiotemporal precision, suitable for 
controlling dynamic reversible biological processes. We can employ these tools to probe 
protein interactions with either gain or loss of function depending on the choice of the 
chemical dimerizer. However, to study the effect of both protein dimerization and 
reversal in the same cell with spatiotemporal resolution, a protein dimerizer able to be 
both turned on and off using light is required. Taking advantage of our modular design, 
we combined both photocage and photocleavable moieties that are sensitive to two 
different wavelengths into a single-molecule dimerizer. This allows for photouncaging 
and photocleavage using wavelength-selective strategy; this novel reversible optical 
	 52 
dimerizer is discussed in Chapter 4. An important feature of our system is the ability to 
wash off unbound free dimerizer; thus, avoiding the hook effect. Finally, the power of 
our modular design facilitates the future development of new dimerizers tailored for a 
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Summary 
Our first generation photocaged chemical dimerizer consists of four components: 
a photolabile protecting group, a photocaged ligand, a flexible linker, and a non-caged 
ligand. For the non-caged ligand, we chose HaloTag system, a covalent ligand/receptor 
pair. For the photocaged ligand, we chose the trimethoprim (TMP) that selectively binds 
to a bacterial dihydrofolate reductase (eDHFR). We use 6-nitroveratryloxycarbonyl 
(NVOC) as a photocage on TMP bound via carbamate linkage. The dimerizer enters 
living cells and covalently binds to the HaloTag protein. Upon illumination, the NVOC is 
released, unveiling the native TMP. The two orthogonal ligands in this system bind 
specifically to their respective cognate receptors with high affinity and the 
heterodimerization of proteins fused to the receptors is rapidly induced. In addition, we 
achieve light-induced recruitment of a cytosolic protein to individual centromeres, 
kinetochores, mitochondria and centrosomes in human cells, demonstrating that our 










The molecular design rationale 
 Most chemical inducers of protein heterodimerization initially developed early 
two decades ago were based on natural products that bind to two receptors sequentially. 
Examples of these molecules include rapamycin, ABA, and gibberellin. Disrupting parts 
of these dimerizers can impact the binding properties significantly, making it difficult to 
modify the native structures for future applications. Therefore, a modular design of 
dimerizers pioneered by the Cornish lab in 20001, offered flexibility and advantages such 
as the ease of structural modification without affecting the ligand binding properties, 
switching ligands for further improvement, and facilitating the future development of 
new dimerizers with additional properties (Chapter 3 and 4). We envisioned that a 
photocaged semi-covalent ligand would be the best choice for us to overcome the 
limitations of existing dimerizers (Chapter 1). Hence, we selected trimethoprim (TMP) 
and HaloTag system based on previous literature precedent and novelty. The HaloTag 
system is referred to both the ligand and receptor protein. For clarity, we will call the 
haloalkane ligand as “Haloligand” or just “Halo” (for short in some cases), and its 
receptor protein is called “Haloenzyme”.  Although both TMP and Haloligand have been 
successfully incorporated in separate dimerizing systems in the past, the combination of 
TMP and Haloligand together had not been reported at the time we conducted our 
research. By changing a ligand, or even one atom in a molecule, the properties of a CID 
system can change dramatically.  
To test whether we could actually use this pair of ligands for protein dimerization 
in living cells, we began by synthesizing the uncaged TMP-Halo, (TH, Figure 2.1). For 
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the first proof-of-principle experiment, we used HeLa cells co-expressing GFP-
Haloenzyme targeted to centromeres by fusing to centromere protein B (CENP-B) and 
cytosolic mCherry-eDHFR. Using confocal fluorescence microscopy for live cell 
imaging, if TH could induce protein dimerization in cells, we would observe the 
colocalization of GFP and mCherry, more specifically, we would see the localization of 
mCherry at centromeres after the addition of TH. As expected, TH successfully induced 
dimerization between Haloenzyme and eDHFR fusion proteins (data obtained by our 
collaborator, the Lampson lab), indicating that TH could be used as a new efficient 
dimerization tool in living system. This has led us to develop the first generation of 
photocaged TH, named NVOC-TMP-Halo (NTH, Figure 2.1). After initial testing of all 
photocaged dimerizers synthesized, we found no difference between NTH derivatives. 
Therefore, we decided to focus on NTH (2) for biological studies. 
Our first photocaged dimerizer (2, Figure 2.2A) that is half-covalent on the non-
caged ligand due to the advantages I have discussed previously. The covalent attachment 
to any protein in the cell serves as an “anchor” for the recruitment of another protein to 
the local target upon uncaging. The sequential binding mode also prevents the hook effect 
as the excess dimerizer can be washed out.  
We can divide our dimerizer design into four modules (2, Figure 2.2A): a 
photolabile protecting group (purple), a photocaged ligand (red), a flexible linker (black), 
and a non-caged ligand (green). For the non-caged ligand and the ligand to be caged, we 
chose a covalent Haloligand, and non-covalent TMP, respectively. TMP selectively binds 
to a bacterial dihydrofolate reductase (eDHFR) over mammalian DHFR with ~1000-fold 
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difference2. The 6-nitroveratryloxycarbonyl (NVOC) was chosen as our first photocage 
on TMP connected via carbamate linkage. Haloenzyme and eDHFR are globular proteins 
of 294 and 158 amino acids, respectively, comparable to GFP (239 amino acids). Both 
Haloenzyme and eDHFR have been successfully fused to the amino (N) and carboxy (C) 
termini of a variety of proteins, making them a promising combination. The detail of each 






























Figure 2.1 | Chemical structures of new dimerizers. The non-caged TMP-Halo, TH (1), the two 




























Figure 2.2 | Design of photocaged dimerizer NTH. (A-B) A chemical structure and schematic 
diagrams of selected NTH (2) and its two receptors: E. coli DHFR (eDHFR) and the Halotag 
protein (Haloenzyme). (B) Schematic of light-induced protein dimerization in living cells via NTH. 
The cell-permeable photocaged dimerizer enters cells and irreversibly reacts with the 
Haloenzyme. Any unreacted dimerizer can be removed by washout. The photocage prevents 
binding with eDHFR before illumination, and is removed by irradiation with 385–405nm light, 





Synthesis of the first generation photocaged dimerizers 
Trimethoprim (TMP) can be caged at two different positions of the exocyclic 
amines in the pyrimidine ring. The two isomers of NTH were isolated (Figure 2.1). In 
addition, two different lengths of linker or spacer between TMP and Haloligand were 
synthesized and tested (data not shown). The first linker for Haloligand (Scheme 2.1) 
was synthesized from a commercially available starting material, 2-(2-aminoethoxy)-
ethanol, which was Boc protected in quantitative yield. The hydroxy group of the 
resulting Boc-protected compound 19 was deprotonated using sodium hydride (NaH) and 
then reacted with the commercially available 1-chloro-6-iodohexane via alkylation to 
obtain the protected Haloligand, compound 20. The Haloligand was deprotected in 1:1 
solution of trifluoroacetic acid (TFA) and dichloromethane (DCM) at room temperature 
(rt) for 2 h, and then extended with succinic anhydride under basic conditions yielding 
the Haloligand with a terminal carboxy functional group, compound 21. The alkyl linker 
for TMP was synthesized in two simple steps from a commercially available starting 
compound via Appel reaction with iodine, triphenylphosphine (PPh3), and imidazole to 
obtain compound 23. TMP ligand was functionalized to obtain compound 24 by first 
selective demethylation of the methoxy group at the para- position to the methylene 
bridge substitution. The desired mono-demethylated TMP 24, was then connected to the 
alkyl linker 23, giving rise to the TMP-NBoc 25, as an intermediate for making both 
uncaged TH and the photocaged NTH. TH was synthesized in the final step by taking 25 
to deprotect the Boc group on the linker and directly couple it to the Haloligand with 
carboxylic group via standard HATU reagent coupling condition using N,N-
 72 
Diisopropylethylamine, or Hünig's base. The photocaged TMP was synthesized from 
compound 25, reacting with the commercially available 4,5-Dimethoxy-2-nitrobenzyl 
chloroformate, under basic conditions in DCM at room temperature for 16 h. This results 
in two regioisomers of the carbamate-caged TMP approximately 1:1 ratio, compound 26 
and 27, because the two exocyclic amines in the pyrimidine ring exhibit similar 
nucleophilic reactivity. These isomers run closely on thin-layer chromatography (TLC) in 
10% MeOH:DCM eluent with compound 26 showing a slightly higher Rf. We isolated 
both isomers, characterized, and confirmed them by 1H, 15N nuclear magnetic resonance 
(NMR) and high-resolution mass spectrometry (HRMS). The key characterization is 
using two-dimension (2D) 1H-15N NMR to observe the correlation between the carbamate 
proton (NH) which shows up ~10 ppm, with the nitrogens in the pyrimidine ring of TMP. 
Both isomers were separately carried on constructing the final products NTH, compound 
2 and 3. Detailed synthetic procedures and characterization can be found in Chapter 5 and 
Appendix. Our initial testing of both isomers for protein dimerization showed no 
apparent difference in the light-induced protein dimerization in CENP-B assay (obtained 
by the Lampson lab), so we decided to focus on compound 2 for other biological 
experiments. Moreover, we have also synthesized a version of NTH that has a longer 
linker between TMP and Haloligand (4) with an increase of ethylene glycol linker by two 
units (6 atoms). The preliminary testing of light-induced recruitment of a cytosolic 
protein to centromeres showed no significant difference, compared to compound 2, under 
the same condition (unpublished data). We therefore decided to continue with the shorter 




























A UV-Vis absorption spectrum of NTH (2) shows the absorbance of NVOC 
moiety in the NTH spans up to ~420 nm with the maxima ~365 nm. This indicates that 
we could use 405 nm laser, a targetable laser available in our lab to uncage the NTH and 
compatible with common wavelengths used for imaging GFP and mCherry, 488 and 594 

























Figure 2.3 | Ultraviolet (UV)–visible absorbance spectra of dimerizers. Chemical structures 
and normalized UV–visible spectra (260–600 nm) of NTH (2, in 90% phosphate-buffered saline 
(PBS) pH 7.4/10% dimethyl sulphoxide), compared to the non-caged analogue TH (1, in 75% 
PBS pH 7.4/25% DMSO). Light sources used for uncaging (387/11, 405 nm) or for imaging (488, 












The NVOC photolabile protecting group 
We initially selected the ortho-nitrobenzyl derivative: ortho-nitroveratryloxy-
carbonyl group (purple colored, Figure 2.2) for various reasons. Firstly, this class of 
photocaging group has been extensively studied and the mechanism of photolysis is well 
understood, allowing us to tune its photo-physical properties. Secondly, it is one of the 
most popular class of photocages employed in the caging of various biomolecules used in 
living cells and organisms. This was indicative that this particular structure would be 
compatible with our biological system. Thirdly, the wavelength of light used for uncaging 
is long enough (>350 nm) that it is not harmful to living organisms. The quantum 
efficiency is high enough so that the uncaging is near quantitative so only a short pulse of 
UV light is required for uncaging, minimizing phototoxicity.  Finally, the byproduct 
generated after uncaging reaction is not toxic to living cells. NVOC has improved 
photoproperties compared to the simplest form of nitrobenzyl derivative (a, Scheme 2.2). 
The dimethoxy substitutions red-shift absorption and increase solubility of the molecule, 
and the rate of photolysis in aqueous solution is reasonably fast. The mechanism of 
photolysis is given (Scheme 2.2). Upon photo excitation, the N-O bond undergoes 
cleavage, forming a radical species in triplet state. Next, the abstraction of the benzylic 
proton by the excited nitro group is followed by the formation of the aci-nitro ring and 
rearrangement to the nitroso derivative. The rapid decarboxylation (CO2) releases the 





























The linker or spacer 
A protein dimerizer can be created by linking any two different known ligands 
with a chemical spacer. The linker must be added to the position of the ligands that do not 
interfere with the binding to protein receptors. Some common chemical linkers are 
alkanes or polyethylene glycol (PEG) derivatives. Pure hydrocarbon linkers may confer 
some solubility issues, therefore PEG linkers are more commonly used due to its 
hydrophilic nature. In our initial molecular designs, we employ a mix of both alkyl and 
ethylene glycol linker due to the convenience of the synthesis. We have since then 
improved and synthesized a version of NTH with a longer PEG linker (4, unpublished). 
With the linker length being the only derivation in our compounds, we have found no 
explicit difference in light-induced recruitment of cytosolic protein to centromeres (2). 
Hence, we decided to continue with the more easily synthesized linker. Moreover, to 
visualize the space between Haloenzyme and eDHFR in a ternary complex, we generated 
a superimposed model by aligning our TMP and Haloligand into reported ligand-bound 
crystal structures (Figure 2.4). We found that two ethylene glycol units was necessary for 
Haloligand binding while a few carbons linked to TMP is sufficient, confirming that the 





















Figure 2.4 | A TMP-Halo ligand bound eDHFR-Haloenzyme ternary complex model. Energy 
minimization and total charges of the ligand structures were performed by using PM6 calculation. 
A TMP-Halo based dimerizer structure was energy minimized using MM2 calculation in Chem3D 
15.0 to obtain the fully extended structure of the linker. The superimposed dimerizer-bound 
ternary protein complex is obtained by using Coot program is used to manually match the 
coordinates of the dimerizer aligned to the individual docked TMP and Haloligand-bound proteins. 
The spacer is indicated by the black box, and in this particular model, it was measured to be ~35 
Å using UCSF Chimera program. The ternary complex structure shows no steric crash between 











The non-caged ligand 
For the non-caged ligand, we chose HaloTag system. HaloTag system is derived 
from a bacterial enzyme, haloalkane dehalogenase, and designed to covalently react with 
a synthetic ligand of choice. A common ligand is a chlorohexane derivative (Figure 2.5). 
The enzyme can be fused to a protein of interest on either N- or C-terminus and the 
recombinant vectors, which are commercially available from Promega. This system 
offers rapid covalent protein labeling that is bioorthogonal in human cells, and commonly 
used for visualization of the subcellular localization, immobilization, or capture of a 
protein of interest3. The HaloTag is a genetically modified active site hydrolase, which 
specifically binds the reactive chloroalkane ligand and has a fast rate of irreversible 
ligand binding (Figure 2.6). Under physiological conditions, nucleophilic attack of the 
aspartate residue in the active site to the ligand displaces the halogen, resulting in the 
formation of a covalent alkyl-enzyme intermediate. In the wild-type hydrolase, this 
intermediate would be hydrolyzed by an amino acid residue, leading to regeneration of 
the enzyme. However, in the modified haloalkane dehalogenase (HaloTag), the mutation 
prevents the reaction intermediate from hydrolysis causing the intermediate to stably 
attach as a covalent adduct (Figure 2.6)3. This system has also been successfully 
















Figure 2.5 | A haloligand-bound haloenzyme docking model. (A) Depicted is a cartoon of a 
Haloligand with an ethylene glycol linker (green stick representation with oxygen atoms shown in 
red) bound in the active site of a haloenzyme (light blue-ribbon diagram, PDB: 1BN7). (B) A 
close-up look in the active site with all amino acid residues involved in the catalysis including key 
residues, aspartate and histidine. This model was created by a default-parameter setting in 


























Figure 2.6 | The mechanism of Haloligand labeling in the HaloTag system. 



























































The caged ligand 
Trimethoprim (TMP) is chosen to be caged in our system due to many reasons. 
First, TMP is an FDA-approved dihydrofolate reductase (DHFR) inhibitor, which is 
highly selective for bacterial DHFR with ~1 nM affinity, >1,000 fold stronger than 
mammalian DHFR2 so we envisioned that it should be cell-permeable and safe for uses in 
living systems. Second, TMP and Escherichia coli DHFR (eDHFR) pair has been well 
validated as a bioorthogonal ligand/receptor pair in eukaryotic cells6. Third, TMP is 
structurally simple and can be derivatized by easy and precedented procedures. Adding a 
linker to the para position of the trimethoxyphenyl ring of TMP has been shown that it is 
not interfering with eDHFR binding (Figure 2.7)6. The 2,4-diaminopyrimidine ring of 
TMP is buried in the tight eDHFR substrate pocket attracted by hydrogen bonds as a key 
interaction, so we speculated that the addition of a bulky photocage to this group would 
effectively block this hydrogen bonding and the DHFR binding (Figure 2.7). A 
photocaged TMP had not been reported, therefore we caged the diaminopyrimidine ring 
of TMP with 6-nitroveratryl carbamate (NVOC). Upon illumination, NVOC rapidly 
decarboxylates allowing photolysis to occur, releasing the native amine of the TMP 
substrate. We joined this photocaged TMP with a Haloligand with a simple chemical 















Figure 2.7 | A TMP-bound eDHFR docking model. (A) Depicted is a cartoon of a TMP 
molecule (pale yellow stick representation with oxygen atoms shown in red; nitrogen, blue; and 
hydrogen, white) bound in the active site of eDHFR (light blue-ribbon diagram, PDB: 1RG7). (B) 
A close-up look in the active site with all amino acid residues involved. This model was created by 











Biological results and discussion 
To test whether NTH is cell-permeable and optimize the efficiency of protein 
dimerization, Dr. Ballister developed an assay for detecting the occupancy of the NTH 
called a dye-blocking assay. We created a cell line expressing Haloenzyme and CENP-B 
and optimized the concentration and incubation times of NTH. To perform the assay, a 
Haloligand attached to a fluorescent dye (Halotag-OregonGreen) was added to the cells 
after the addition and incubation of NTH. Unoccupied Haloenzyme active sites are 
labelled with this green fluoresecent dye, while any occupied sites block this reaction. 
Cells untreated with NTH serve as a control normalized to 100% of green fluorescent 
signal, indicating saturation of the Haloenzyme sites by Halotag-OregonGreen. Relative 
fluorescent signal compared to the control was plotted as a function of NTH 
concentration and incubation time (Figure 2.8). We found that 20 µM NTH incubated for 
1 h was the optimal condition for dimerization at centromeres. Using these conditions, we 
determined the kinetics of recruitment of cytosolic proteins to centromeres. Upon a short 
pulse of UV illumination to the cells pre-incubated with NTH, mCherry-eDHFR was 
rapidly recruited to centromeres with a t1/2 of ~15 s (Fig. 2.9). No such effect was 
observed in control experiments when cells were repeatedly exposed to 488 nm light or in 
the absence of NTH (Figure 2.10). Next, we used a pointable 405-nm laser to achieve 
rapid and spatially defined recruitment to an individual centromere, indicating controlled 
protein dimerization with high spatiotemporal resolution in living cells (Figure 2.9). We 
also show that the NTH-induced dimerization can be reversed by adding the free TMP 
ligand to competitively bind to eDHFR. Furthermore, to apply our new tool to other 
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locations in the cell, we constructed Haloenzyme–GFP fusion proteins anchored to 
kinetochores, centrosomes and mitochondria (Figure 2.11).  
Kinetochores are protein complexes, which assemble at centromeres and serve as 
attachment points for spindle microtubules and signaling hubs for mitotic checkpoint. We 
fused Haloenzyme-GFP to the kinetochore protein Nuf2, which localizes to the outer 
kinetochore, proximal to the microtubule binding site. Centrosomes are the primary 
micro-tubule organizing centers of animal cells. The replication and positioning of these 
organelles are tightly regulated and linked to polarized cell division and cancer. We target 
Haloenzyme to centrosomes by fusing it to centrosome localizing domain from AKAP9. 
Centromeres, kinetochores and centrosomes are not membrane-bound, so we chose 
mitochondria as a representative for a membrane-bound organelle. Mitochondria are 
structurally unique organelles involved in oxidative metabolism and apoptotic signaling 
among other critical cellular pathways. Dysfunction of mitochondria often leads to 
mitophagy which is strongly associated with neurodegenerative diseases and cancer. We 
fused haloenzyme to the C-terminal domain of the Listeria monocytogenes ActA protein 
which localizes to the mitochondrial outer membrane and is exposed to the cytosol. All 
three of these Haloenzyme–GFP-fused proteins were expressed and localized properly, 
and we successfully performed light-induced recruitment of mCherry–eDHFR to 
individual structures in all of these locations using short pulses (10–100 ms) of 405 nm 
laser illumination (Figure 2.11). Together, these results demonstrate that NTH functions 
robustly at a diverse set of organelles (mitochondria, kinetochores and centrosomes, 
DNA binding protein, and centromeres.) To test the limitation of precision of our system, 
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we were able to successfully recruit an individual kinetochore within a pair of sister 
kinetochores separated by ~1 mm (Figure 2.11). This highlights the power of our system 


















Figure 2.8 | NTH enters living cells. The extent of NTH reaction with CENP-B-Haloenzyme as a 
function of NTH concentration or treatment time was measured using a dye-blocking assay. Cells 
expressing CENP-B-Haloenzyme (without GFP) were incubated with NTH, washed, treated with 
100nM Halotag-Oregon Green (Halo-OreGrn) for 20 min, then washed again before imaging. 
Decreased Halo-OreGrn indicates NTH occupancy of CENP-B-Haloenzyme sites. Each Halo-
OreGrn image is displayed at two brightness levels to aid visualization. Within each row, all the 
images are displayed using identical brightness levels. (A,B) Cells were treated with 1, 5, 10 or 
20 µM NTH for 1 h, then treated with Halo-OreGrn as described above. Treatment with 10 µM 
NTH for 1 h is sufficient to block ~90% of Halo-OreGrn binding. (C,D) Cells were treated with 20 
µM NTH for 15, 30 or 60 min, or left untreated as control, then treated with Halo-OreGrn as 
described above. Treatment with 20 µM NTH for 30 min is sufficient to block ~90% of Halo-
OreGrn binding. Images (A,C) are maximum-intensity projections of representative cells from 
each condition. Average Halo-OreGrn intensity at centromeres was quantified for each condition 













Figure 2.9 | Light-induced dimerization at centromeres. Cells expressing CENP-B–GFP-
Haloenzyme and mCherry–eDHFR were treated with 20 µM NTH for 1 h, then washed before 
imaging. (A) Cell-wide recruitment of mCherry–eDHFR to centromere-localized CENP-B–GFP–
Haloenzyme in response to a 2-s pulse of 387(±5.5) nm light. (B) Average mCherry–eDHFR 
centromere intensity at time points before and after uncaging, error bars represent s.d. (n.10 
cells). (C) A single centromere (indicated by arrowhead in inset) was irradiated with a 405-nm 
laser to induce mCherry–eDHFR recruitment. Insets show boxed regions in GFP (top row) and 
mCherry (middle row) and colour-merge (bottom row) from indicated time points. Scale bars, 5 or 

























Figure 2.10 | No-dimerizer and 488 nm excitation negative controls. (A,B) Cells were 
expressing CENP-B-GFP-Haloenzyme and mCherry eDHFR. (A) Cells without any small 
molecule treatment were exposed to a 2-s pulse of 387(±5.5) nm light. No change in mCherry-
eDHFR localization was observed, indicating that UV light does not cause mCherry-eDHFR 
recruitment to centromeres in the absence of NTH. (B) Cells treated with 20 μM NTH for 1 hour 
were imaged hundreds of times in the GFP channel, using maximum 488 nm laser intensity. GFP 
and mCherry images after 100 s and 250 s of cumulative 488 nm laser exposure are shown. No 
change in mCherry-eDHFR localization is detectable, demonstrating that NTH is functionally 
insensitive to 488 nm light. 
UV exposure without NTH 





Figure 2.11 | Dimerization at individual mitochondria, centrosomes and kinetochores. Cells 
expressing mCherry–eDHFR and Haloenzyme–GFP-anchor domain fusion proteins specific for 
(A) mitochondria (ActA), (B) centrosomes (AKAP9) or (C) kinetochores (Nuf2) were incubated 
with 20 µM NTH for 1 h, then washed before imaging. Cells were imaged before and after 
targeted laser illumination, as indicated. Individual structures in these cells (indicated by 
arrowheads in insets) were targeted with a 10–100 ms pulse from a 405-nm laser immediately 
before the ‘post’ image. Insets show boxed regions in GFP (top row) and mCherry (middle row) 
and color-merge (bottom row) from indicated time points. GFP is locally photobleached by the 
405-nm uncaging pulse. Gaussian smoothing with a radius of 1 pixel was applied to mCherry 
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Summary 
Optogenetic techniques have emerged as important tools to probe dynamic 
cellular processes such as organelle transport, cell signaling and polarity. These 
techniques have the potential to provide both spatiotemporal control and molecular 
specificity by using light and genetically encoded protein tags, respectively. We have 
previously reported a photocaged chemical dimerizer NTH, that can recruit tagged 
proteins from the cytosol to multiple cellular structures (Chapter 2). Using this molecule, 
dimerization can be reversed by the addition of excess TMP as a competitor, but a major 
limitation of this is that reversal is slow and lacks spatial control. One feature of our CID 
system is the modular design of the dimerizers, which facilitates the development of new 
molecules on the same platform. Here we exploit this design by developing two new 
dimerizers. One can be uncaged using less light and longer wavelengths, while the other 
allows reversal of dimerization so that proteins can be recruited to and subsequently 
released from cellular structures using light. We use these dimerizers to control 
peroxisome transport as a proof-of-principle. Furthermore, we apply these dimerizers to 
optogenetically control kinetochore function, which will not be discussed in this thesis, 







Novel optogenetic tools 
Our previously reported dimerizer, NTH1 (2, Chapter 2, Figure 3.1A), composed 
of four important modules: 6-nitroveratryl oxycarbonyl (NVOC) photocage (purple) to 
prevent untargeted dimerization; trimethoprim (TMP, red), which non-covalently binds to 
Escherichia coli dihydrofolate reductase (eDHFR); Haloligand (green) that covalently 
binds to a bacterial alkyldehalogenase enzyme (referred to as Haloenzyme; and a linker 
(black). Upon Illumination, the photocage is removed, allowing dimerization of eDHFR-
tagged proteins with Halo-tagged proteins. Based on this modular design, we developed 
two new dimerizers (5 and 6, Figure 3.1A) that offer additional properties: increased 
sensitivity to light (Figure 3.1B; Figure 3.2) and rapid light-induced reversal of 
dimerization, respectively (Figure 3.2). 
 
Development of a new photocaged dimerizer 
We replaced the NVOC with a [7-(diethylamino)-coumarin-4-yl]methyl 
(DEACM) photocage, which is more sensitive to light and can be uncaged at longer 
wavelengths (Figure 3.1A). The synthesis of this molecule is discussed in the next 
section of this chapter; details and characterization can be found in Chapter 5. This new 
molecule, DEACM-TMP-Haloligand (CTH) (5, Figure 3.1A), enters living cells, as 
shown in cells expressing Haloenzyme fused to the centromere protein B (CENP-B) 
(Figure 3.3A), and is not toxic to cells at the concentrations used in our experiments 
(Figure 3.3B). To show that CTH can recruit proteins from the cytosol to cellular 
structures, we targeted mCherry to mitochondria by uncaging CTH with 385 nm light. At 
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this wavelength, CTH requires less light than NTH to uncage (Figure 3.4A). The 
DEACM photocage can also be uncaged with 444 nm light, whereas NTH is only 
sensitive to shorter wavelengths (Figure 3.4B).  
 
The photocleavage mechanism of DEACM 
The general mechanism of DEACM is different from that of NVOC. Initially, 
light absorption of DEACM generates π-π* excited singlet state (Scheme 3.1)2, which 
can undergo either unproductive, non-radiative decay and fluorescence relaxation, or the 
desired heterolytic C−X bond cleavage. There is evidence supporting SN1 cleavage2 at 
this carbon using 18O-labeled water. The solvent caged tight ion pair, (coumarin-4-
yl)methyl cation and the leaving group conjugate base is the key intermediate. The cation 
either reacts directly with surrounding nucleophiles or solvent (usually water in 
biological systems) to form a new stable coumarylmethyl product. Although the 
heterolytic bond cleavage is very fast, the tight ion pair dominantly recombines to 
regenerate the ground-state DEACM caged compound in an alternative non-productive 
pathway (Scheme 3.1). Poor leaving groups such as alcohols, phenols, thiols, and amines 
can render (coumarin-4-yl)methyl derivatives resistant to photoheterolysis. Thus, caging 
these groups through a carbonate or carbamate linkage in our strategy is more efficiently 
released. Decarboxylation of the released carbamate anion, which is the rate-limiting 
step, is strongly dependent on the pH and on the nature of the released amine or amino 
acid, but this is usually rapid at the physiological pH. Concomitantly, our substrate, TMP, 
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exhibits fast release, likely because the aromatic amine leaving group is 




















Figure 3.1 | New dimerizers. (a) Chemical structures of CTH and TNH, (b) UV-Vis absorption 





















Figure 3.2 | New dimerizers based on a modular design and the concepts. (A) Light-induced 
protein dimerization using CTH, a coumarin-based photocage that is more sensitive to light, and 
absorbs longer wavelengths, compared to previously developed NVOC photocage. (B) Light-
induced reversal of protein dimerization using TNH. NVOC is inserted in the linker between TMP 





































Figure 3.3 | Cell-permeability and cytotoxicity of CTH and TNH. (A) CTH enters live cells. 
HeLa cells stably expressing Haloenzyme-GFP fused to the centromere protein CENP-B were 
incubated with 10 μM CTH for various times, or with various concentrations of CTH for 60 min, 
then a dye that binds to Haloenzyme (JF585, HHMI Janelia Research Campus) was added to 
visualize any sites not occupied by CTH. (B) The Halo dye JF585 signal in A was plotted as a 
function of CTH concentration and incubation time. (C) CTH and TNH are not cytotoxic at the 
concentrations used in our experiments. Cells were incubated with the dimerizers for 24 h, which 
is much longer than our usual experimental time (2-3 h), and the AlamarBlue cell viability assay 
was used to measure toxicity. CTH and TNH are not cytotoxic up to 50 μM and 1 μM, 
respectively, which are at least 5-fold higher than the concentrations used in our experiments. 














Figure 3.4 | Light-induced protein dimerization at mitochondria as a proof-of-concept for 
CTH. (A) Cells expressing mCherry-eDHFR and Halo-GFP-ActA, which localizes to mitochondria, 
were incubated with 10 μM CTH or NTH. Cells were illuminated with a 100-ms pulse of wide-field 
UV (387 ± 5 nm), which was sufficient to uncage CTH but not NTH, followed by a 2-s pulse to 
uncage NTH. The localization mCherry at mitochondria can be easily observed when the 
dimerization occurs. (B) CTH is uncaged by 444 nm light whereas NTH is not. Cells expressing 
mCherry-eDHFR and Halo-GFP-ActA, as described above, were incubated with either 10 μM 
CTH or 10 μM NTH. mCherry-eDHFR was recruited to mitochondria by uncaging CTH with a 
444-nm light pulse, but NTH was not affected. (C) Graph shows average intensity of mCherry at 




Development of a new photocleavable dimerizer 
Due to limited spatially controlled and slow reversibility of our first generation 
dimerizer by the addition of TMP competitor1, we developed a new dimerizer that can be 
cleaved with light to reverse dimerization. Taking advantage of the modular design of our 
system, we inserted a cleavable NVOC linker in between the Haloligand and TMP 
ligands to make TNH (6) (Figure 3.1A). The synthesis of this molecule is discussed in 
the next section of this chapter and more details and characterization can be found in 
Chapter 5. To show that TNH enters living cells and recruits proteins to cellular 
structures, we targeted mCherry-eDHFR to mitochondria. The kinetics of recruitment 
depend on TNH concentration (Figure 3.5), with the highest degree of dimerization (t1/2 
~2 min) observed at 0.1 μM. A higher concentration of TNH (1 μM) is less effective, 
because independent occupancy of both protein binding sites with two different TNH 
molecules would lead to unproductive protein–ligand complexes (the hook effect as 
discussed in Chapter 1). A lower concentration (0.01 μM) required more time (t1/2 ~5 
min) to achieve maximum dimerization, which is ~80% of the maximum dimerization 
obtained with 0.1 μM. TNH is not toxic to cells at these concentrations (Figure 3.3B). To 
test whether the recruitment of proteins can be reversed with light, we targeted multiple 
regions sequentially with a 405-nm laser (Figure 3.5B). mCherry was released rapidly in 





Peroxisome transport assay as a functional test 
As a functional test of the two new dimerizers, we used them to control organelle 
transport. We previously showed that recruitment of kinesin or dynein motors to 
peroxisomes induces transport to the periphery or center of the cell, respectively3. 
Recruiting the dynein adaptor Bicaudal-D (BICD) to peroxisomes by uncaging CTH led 
to peroxisome accumulation at the cell center, as expected (Figure 3.6). To show that 
transport can be halted by reversing dimerization, we used TNH to recruit an N-terminal 
fragment of kinesin light chain 1 (KLC1) to peroxisomes, and subsequently cleaved it 
with light on one side of the cell (Figure 3.7, yellow region). After incubation with TNH, 
but before photocleavage, peroxisomes were partially depleted from the interior of the 
cell, showing the recruitment of the organelle to BICD. After illumination, peroxisomes 
remained stationary on the cleaved side of the cell, but depletion continued on the 
uncleaved side. Furthermore, peroxisomes accumulated in peripheral regions, where MT 
plus ends are located, on the uncleaved side, as expected for kinesin-mediated transport 
(Figure 3.7A and B). These results demonstrate that organelle transport induced by 


























Figure 3.5 | Light-induced reversal of protein dimerization at mitochondria using TNH.  
(A) TNH recruitment kinetics depends on TNH concentration, and the recruitment can be 
reversed by cleavage of TNH with UV light. TNH was added at t=0 at the indicated 
concentrations. (B) Graph shows average intensity of mCherry at mitochondria, quantified as 
described in methods (chapter 5). Error bars represent standard deviation. Scale bars 10 μm. (C) 
Cells expressing mCherry-eDHFR and Halo-GFP-ActA were incubated with 100 nM TNH to 
recruit mCherry to mitochondria. Three regions (outlined in yellow, red or blue) were illuminated 
sequentially with a 405-nm laser to cleave TNH and release mCherry from mitochondria. Merged 















Figure 3.6 | Control of peroxisome transport with CTH. Cells expressing BICD-mCherry-
eDHFR and PEX3-GFP-Halo, which localizes to peroxisomes, were treated with 10 μM CTH. 
CTH was uncaged with 444 nm light at t=0 to induce peroxisome transport towards the 
centrosome. Graph shows GFP intensity at the accumulation region (indicated by yellow arrows), 
which was quantified as described in methods (chapter 5). The kinetics of induced peroxisome 
transport are different depending on the time of light exposure. Error bars represent standard 
deviation (N=18 and 16 cells for 0.1 second and 3 seconds illumination time, respectively). Scale 












Figure 3.7 | Control of peroxisome transport with TNH. (a) Cells expressing kinesin light chain 
1 (KLC1)-mCherry-eDHFR and PE X3-GFP-Halo, which localizes to peroxisomes, were treated 
with 100 nM TNH at t = −4 min to induce peroxisome transport toward the cell periphery. Half the 
cell (yellow region) was illuminated with a 405-nm laser at t = 0 to cleave TNH. GFP intensity was 
quantified (f) in the interior region (1), where TNH was cleaved, and in interior and peripheral 
regions (2 and 3, respectively) that were not exposed to 405 nm light. Intensity in each region 













Synthesis of CTH (Scheme 3.2) 
The linker between TMP and Halo was previously synthesized using the same 
method to functionalize the chlorohexane with a carboxylic acid functional group, 21 
(Chapter 2). 7-(Diethylamino)-4-(hydroxymethyl)coumarin (DEACM) was synthesized 
according to the modified procedures from literature. Oxidation of the allylic carbon of 
the coumarin, 28, using selenium dioxide (SeO2) under reflux in p-xylene for three days 
gave the corresponding aldehyde, which was then reduced by sodium borohydride 
(NaBH4) to obtain DEACM, 29, in 10% yield overall. Although we tried to improve the 
yield by adding SeO2 multiple times and extending the time for refluxing, the yield is 
generally low according to many reported procedures, most likely due to the quality of 
SeO2 and the complications during column chromatography. We found that different lots 
and brands of SeO2 gave inconsistent results. However, by changing the conditions, we 
were able to improve the yield and reduce the cost of synthesizing TMP-NBoc, 25, which 
is the key intermediate for making both NTH, CTH, and TNH as well as other 
compounds in the future. We used 3-bromopropylamine, which is less expensive than the 
iodo-derivative, with a milder condition using 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) 
in dimethyl sulfoxide (DMSO) at room temperature (rt) overnight. For CTH, TMP was 
DEACM-caged via carbamate linkage utilizing a different method used for NVOC cage. 
The chloroformate derivative of DEACM could also be employed to make DEACM-
caged TMP, in a similar manner to the NTH, but it suffered from low yields due to 
sequential reactions and separation of isomers. Therefore, a better synthesis was devised 
for CTH. TMP-NBoc was added with 1.5 equivalent of 1,1'-carbonyl-diimidazole, 
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Hünig’s base, and a catalytic amount of 4-(dimethylamino)pyridine (DMAP), then 
refluxed in DCM for 2 h. The tandem liquid chromatography-mass spectrometry (LCMS) 
technique was used to monitor the reaction. The activated TMP intermediate with CDI 
can be trapped by methanol and detected with the mass to charge ratio (m/z) of 550.24, 
indicating the conversion to the starting material into the methanol adduct. DEACM was 
then added into the reaction flask, and stirred at rt overnight to gain the DEACM-TMP-
NBoc, 30. Surprisingly, we found that using this method, exclusively, the para-DEACM 
caged isomer was observed as a major product. Unlike the DEACM chloroformate 
electrophile, this CDI-activated TMP intermediate offers a higher selectivity. More 
computational studies to determine the reactivity of this intermediate are needed to 
confirm this observation. The HATU reaction was performed using the same method 


































































































Scheme 3.2 | Synthesis of Coumarin-caged TMP-Halo ligand, CTH, (5). 
Reagents and conditions: (a) i) SeO2, p-xylene, reflux, 3 days; ii) NaBH4, THF:EtOH (1:1),       
25 oC, 4 h, 10% (two steps) (b) 48% HBraq ,  100 oC, 30 min, 48%  (c) tert-butyl-3-
bromopropylcarbamate, DBU, DMSO, 25 oC, 16 h, 56%  (d) i) CDI, DIEA, DMAP, DCM, reflux,    
2 h; ii) 29, DIEA, DMAP, DCM, 25 oC, 16 h, 12% (two steps)  (e) i) TFA:DCM (1:3), 25 oC, 2 h; ii) 
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Synthesis of TNH (Scheme 3.3) 
To synthesized TNH, the NVOC needed to be functionalized, so that it can be 
attached to both TMP and Haloligand. We envisioned that the methoxy group at the 
meta- position to the nitro group could be an attachment point and there was precedent 
that Haloligand could be linked to this functional group. Inspired by the literature 
precedent4, we redesigned the linker for Haloligand while TMP linker remained the same. 
Haloligand, 33, was synthesized by mono-alkylation of the tetraethylene glycol (4EG, 31) 
with 1-bromo-6-chlorohexane, followed by the Appel reaction to convert the hydroxy 
group into bromo derivative, 32. For the NVOC moiety functionalization, Vanillin was 
benzyl protected, followed by the nitration reaction to selectively install a nitro group at 
the para- position to the methoxy group and ortho- position to the aldehyde group, 36. 
This was achieved by dropwise adding fuming nitric acid (>90% concentrated) in a flask 
with 35 dissolved in 1,2-dichloroethane at -30 oC for 2-3 h. Precaution and protective 
gears should be taken seriously as the fuming nitric acid is highly corrosive. Deprotection 
of the benzyl protecting group was done using 48% aqueous solution of hydrobromic 
acid (HBr) at 90 oC for 3 h but it suffers from low yield (23%). I later found a better 
method using pure trifluoroacetic acid (TFA) as both reagent and solvent, which results 
in a cleaner reaction and desired product without having to do a column chromatography 
(unpublished). The nitro vanillin, 36, was then reacted with the bromo derivative of 
Haloligand, 33, to obtain 37, which was then reduced by sodium borohydride (NaBH4) to 
achieved 38. A key step to make TNH is the formation of carbamate linkage, which is 





























































chloroformate with DMAP in DCM as a solvent at room temperature overnight, then 


















Scheme 3.3 | Synthesis of the photocleavable TMP-NVOC-Halo ligand, TNH, 3. 
 
Reagents and conditions: (a) NaH, 1-bromo-6-chlorohexane, THF:DMF (2:1), 0 oC to  
25 oC, 16 h, 40%;  (b) PPh3, CBr4 THF, 25 oC, 16 h, 50%;  (c) K2CO3, benzyl bromide, DMF, 80 
oC, 16 h 99%;  (d ) i) Fuming HNO3, 1,2-dichloroethane  -30 oC to 25 oC, 3 h  ii) 48% HBraq 90 oC, 
3 h, 23% (two steps);  (e) 33, K2CO3, DMF, 60 oC, 16 h, 30%;  (f) NaBH4, MeOH:Dioxane (1:1) 0 
oC to 25 oC, 2 h, quantitative yield; (g) i)  4-Nitrophenyl chloroformate, DMAP, DCM, 25 oC, 16 h 
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Summary 
Many dynamic biological processes are regulated by protein-protein interactions, 
which are highly dynamic and often reversible. Chemically-induced dimerization (CID) 
has been used to study reversible cellular events, especially cell signaling networks. 
Previously, we reported two dimerizers CTH and TNH with which light can be used to 
turn on and off protein dimerization, respectively. However, to date no chemical 
dimerizer that can be both rapidly activated and deactivated with high spatiotemporal 
resolution has been reported. Herein, we present a novel chemical inducer of protein 
dimerization that can be rapidly turned on and off using single pulses of light at two 
orthogonal wavelengths. We demonstrate the utility of this molecule by controlling 
peroxisome transport and mitotic checkpoint signaling in living cells. Our system 
highlights and enhances the spatiotemporal control offered by the CID technique. This 
new tool will be useful for addressing and uncovering biological problems on a single 










Introduction to a light-controlled ON-OFF chemical switch for protein dimerization 
 To dissect complex biological interactions that are highly dynamic and often 
reversible, experimental tools that can reversibly manipulate protein interactions with 
comparable precision are necessary. Some major limitations of existing chemically-
induced dimerization (CID) systems inspired us to develop a new optogenetic system by 
introducing light control to the CID technique (Chapter 2). We previously reported 
photocaged chemical dimerizers that allow protein recruitment with light to many 
subcellular locations, such as centromeres, kinetochores, mitochondria, peroxisomes, and 
centrosomes (Chapter 2 and 3), and a photocleavable dimerizer for which light can be 
used to reverse dimerization (Chapter 3). However, to study both the gain and loss of 
function of protein recruitment in the same cell with spatial and temporal control, a novel 
dimerizer that can be both activated and deactivated by light is required. Currently, no 
CID system with such ability has been reported. To accomplish this goal, we created a 
novel molecule based on the modular design of our previous dimerizers. Herein, we 
report a cell-permeable photocaged-photocleavable dimerizer that is capable of turning 
on and off protein dimerization using two orthogonal wavelengths of light (Figure 4.1). 
The dimerizer rapidly induces protein dimerization and dissociation within seconds upon 
illumination at various locations in the cell, such as mitochondria, centromeres, and 
plasma membrane. Furthermore, we demonstrate the utility of our new system by 
controlling peroxisome transport and mitotic checkpoint signaling with high 
spatiotemporal resolution. To the best of our knowledge, this is the first rapidly photo-
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inducible and reversible chemical dimerizer that can be completely controlled by light on 

































Figure 4.1 | The light-controlled ON-OFF switch for protein dimerization. (A) Chemical 
structure of the optimized CTNH structure, 9. (B) the concept of using CTNH for light-induced 










Rational design of the light-controlled system 
To create a light-induced reversible dimerizer, we take advantage of the modular 
design of our CIDs. Based on previously developed dimerizers (Chapter 3), we showed 
that [7-(diethylamino)coumarin-4-yl] methyl (DEACM) in CTH could be uncaged with 
444 nm light. At this wavelength, NTH is unaffected due to the nitroveratryl (NV) having 
a more blue-shifted absorbance compared to DEACM (Chapter 3). Thus, we were able to 
correctly predict these two photocages could be used in conjunction with one another for 
sequential photoactivation. We employ the principle of  photolabile functional groups and 
chromatic orthogonality, which allow for wavelength-selective photo-uncaging1,2. 
Although DEACM has a significantly higher photon absorption and high quantum 
efficiency at 440 nm, NV exhibits its highest absorption at 365 nm but almost no 
absorption at >400 nm. In addition, the absorption spectra of DEACM and NV are 
sufficiently blue-shifted to protect them from undesired cleavage at wavelengths 
commonly used for imaging (e.g., 488 nm) (Figure 4.2). Therefore, we selected this pair 
for use in our strategy. DEACM (blue moiety in the chemical structure) serves as a 
photocage and NV (purple moiety) is incorporated into the linker between the two 
ligands of the dimerizer (Figure 4.1A). 
 To function successfully in living cells, the dimerizer must enter the cell and form 
a stable complex with the first receptor (Haloenzyme) for the non-caged ligand. 
Illumination with the first wavelength (444 nm) selectively removes the DEACM 
photocaging group without cleaving the NV linker, which initiates binding to the receptor, 
eDHFR. Another important property is the stability of the chemically induced dimerized 
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protein complex, which should persist over the course of the experiment and undergo 
efficient photocleavage only after illumination with the second wavelength (387-405 nm), 
which photocleaves the dimerizer to reverse the protein dimerization (Figure 4.1B). 
After removing DEACM and activating TMP-NV-Halo induced protein dimerization, the 
photosensitive linker could be buried inside the protein complex, which would diminish 
the photocleavage efficiency. Thus, the photocleavable linker should be optimized to 
allow the NV group to be fully exposed outside the dimerized protein complex for 
efficient photolysis. We speculated that the addition of an ethylene glycol moiety 
between the caged TMP and the NV photocleavable linker attached to the Haloligand 
would be useful. We began with a crude model for the structure of the TMP-NV-Halo 
dimerizer complexed with Haloenzyme (PDB: 1BN7) and eDHFR (PDB: 1RG7) to 
visualize the space between the two ligands, TMP and Halo. The length of the designed 
chemical spacer in 9 was determined to be ~35 Å in the fully extended conformation. The 
NV group was also exposed outside the protein complex. Virtually no steric interactions 





















































































































































Synthesis of the new dimerizers 
Building upon our previously established system (Chapter 2 and 3), we designed 
and synthesized new dimerizers (Figure 4.3), composed of four modules: (7- 
Diethylaminocoumarin- 4- yl)methyl (DEACM) photocage, a caged trimethoprim (TMP) 
ligand, a photocleavable nitroveratryl (NV) linker and a non-caged HaloTag (Halo) 
ligand. Employing the synthesis framework similar to that of CTH and TNH (Chapter 3), 
CTNH1, 7 (Figure 4.3) was first synthesized as the simplest version of CTNH with the 
shortest linker between TMP and Haloligand. CTNH, 7, was tested in live cell 
mitochondrial assays (results obtained by Dr. Ballister and later repeated by myself). We 
found that the dimerization was induced prior to light-activation, indicating two 
possibilities: either the molecule was contaminated with the non-caged TNH or 7 
decomposed in the dark or quickly hydrolyzed in the cell media, giving rise to TNH. 
After re-synthesis and HPLC purification of several different batches of 7, the issue 
persisted. Therefore, we ruled out the possibility of contamination. To test whether 7 was 
decomposing to TNH in the dark, an HPLC assay was conducted to monitor the 
decomposition progression. It was observed that 7 underwent hydrolysis in the dark, and 
we suspected it was likely due to the slightly acidic TFA/water that may catalyze 
decomposition (data not shown). Changing the HPLC solvent to pure water still gave 7 
that was contaminated with TNH. To confirm that 7 was being hydrolyzed in water, a 
live cell assay for protein dimerization at mitochondria was conducted. Cells expressing 
Haloenzyme-GFP-ActA (mitochondria targeting motif) and mCherry-eDHFR fusion 
proteins, were added with freshly HPLC purified 7, and then monitored live on the 
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microscope in GFP and mCherry channels, which do not uncage CTH normally. Without 
any photoactivation, protein dimerization occured after ~15 min, indicating that 7 
underwent hydrolysis or uncaging in the dark with the half-life of about 15 min. This led 
to the synthesis of 8 and 9 (Figure 4.3). It is possible that two different moieties in a 
small molecule interact, such as in Fluorescence Resonance Energy Transfer (FRET) or 
photo-induced electron transfer (PET). It is plausible that an intramolecular interaction 
between the two photo-sensitive groups, NV and DEACM contribute to the hydrolysis in 
the dark. Moreover, there is literature precedent that some photocaged molecules undergo 
dark-hydrolysis3-4. To improve the design of the dimerizer and prevent hydrolysis, NV 
and DEACM were separated farther away from each other. By adding a longer linker to 
7; 8 and 9 was synthesized. The isomers were isolated to test if one would function better 
than the other. The separation of 8 from TNH was difficult as it runs closer to the 
uncaged contaminant than 7. Therefore, only 9 was successfully isolated. Using the same 
mitochondrial assay to test dimerizer 7, Compound 9 was no longer hydrolyzed in the 
dark, indicating that 9 is significantly more stable than Compound 7.  
CTNH, 9 was synthesized by forming connections between three parts as follows 
(Scheme 4.1): DEACM-caged TMP, a functionalized ethylene glycol linker, and the 6-
nitroveratryl alcohol attached to the Haloligand. The diaminopyrimidine ring of TMP was 
caged via a carbamate linkage, which rapidly decarboxylated upon photocleavage to 
release the native amine. For the full synthetic scheme, see Scheme 4.2. The regioisomer 
of the DEACM-caged TMP was confirmed by nuclear magnetic resonance (NMR).  The 
correlation between the protons of -NH2 and the two nitrogen atoms in the pyrimidine 
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ring of TMP was observed in the 1H-15N HMBC (Figure 4.4). The correlation between -
NH and the protons of the methylene bridging between the two aromatic rings of TMP 
was also observed in the Nuclear Overhauser Effect Spectroscopy (NOESY) results, 
confirming that the carbamate linkage on the nitrogen atom is ortho to the methylene 
























































































































































































Scheme 4.2 | Chemical synthesis of CTNH (9). 
 
Reagents and conditions: (a) NaH, 1-bromo-6chlorohexane, THF/DMF (2:1), 0 to 25 oC, 16 h, 
40%  (b) PPh3, CBr4, THF, 25 oC, 16 h, 50%  (c) SeO2, p-xylene, reflux 3 days; (d) NaBH4, 
THF/EtOH (1:1), 25 oC, 4 h, 20% (2 steps) (e) 48% HBraq, 100 oC, 30 min, 48% (f) tert-butyl-3-
bromopropylcarbamate, DBU, DMSO, 25 oC, 16 h, 42%  (g) i) 15% Phosgene in Toluene, DIEA, 
THF, 0 oC, 2 h;  ii) 25, DIEA, DCM, rt, 16 h, 20%  (h) K2CO3, benzyl bromide, DMF, 80 oC, 16 h, 
99%  (i) Fuming HNO3, 1,2-dichloroethane -20 oC to 25 oC, 16 h, 50%  (j) 48% HBraq, 90 oC, 3h, 
23% (k) 33, K2CO3, DMF, 60 oC, 16 h, 60% (l) NaBH4, MeOH/Dioxane (1:1), 0 to 25 oC, 2 h, 
quantitative  (m) 4-Nitrophenyl chloroformate, DMAP, DCM, 25 oC, 24 h  (n) tert-butyl (3-(2-(2-(3-
Br O O O O ClHO O O O O ClHO
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aminopropoxy)ethoxy)ethoxy)propyl)carbamate, DIEA, DMAP, DCM, 25 oC, 16 h 16%  (o) i) 
TFA/DCM (1:1), 0 to 25 oC, 2 h; ii) succinic anhydride, Et3N, DCM, 25 oC, 16 h, 90% (2 steps) (p) 


























Figure 4.4 | Characterization of DEACM caged TMP.  (A) Key NOE and 15N-HMBC 
correlations observed in NMR experiment. (B) Optimized geometry structure of DEACM caged 




CTNH cell-permeability and cytotoxicity  
To determine the cell permeability and optimal concentration of CTNH, we 
performed the previously established Halo ligand dye displacement assay (chapter 2) 
with cells expressing centromere protein B (CENP-B) fused to GFP-Haloenzyme. 
Incubating cells with 20 µM CTNH for 30 min blocked more than 90% of the Halo 
ligand red dye (JF585) binding, indicating that CTNH enters the cells and occupies the 
haloenzyme active sites (Figure 4.5). Furthermore, CTNH is not toxic to cells at 
concentrations up to 20 μM for 24 or 48 h, indicating that it is suitable for long-term live 


































Figure 4.5 | Determination of concentration and incubation time for treatment of cells with 
CTNH. HeLa cells stably expressing CenpB-GFP-Halo were treated with CTNH (A) at 20 µM, 
then incubated for 15, 30, and 60 min. (B) at 5, 10, and 20 µM, then incubated for 1 hour. 
Untreated cells were used a control and normalized to 100% uptake of CTNH. Subsequently, all 
cells were washed out and then, treated with Halo red dye (JF585) at 0.5 µM for 15 min, followed 
by 15 min wash-out prior to imaging. Confocal images reveal that treating cells with CTNH at 20 
µM for 30 min is suffucient to block >90% of Halo red dye (JF585) binding, indicating that CTNH 
enters cells and covalently occupies Haloenzyme active site. Error bars represent s.d.  (n >10 




























Figure 4.6 | AlamarBlue cell viability assay. HeLa cells were incubated with various 
concentrations of CTNH, DMSO and camptothecin as a positive and negative control, 
respectively, in 96-well plates. After 24 h and 48 h incubation, cells were washed with fresh media 
and stained with AlamarBlue reagent according to the manufacturer’s protocol. A plate reader 
was used to detect the fluorescence signal from metabolically active cells. No significant cell 
death was observed with CTNH up to 20 µM and 48 h incubation, compared to the negative 
control. Each experiment was performed with four replicates. Averages were calculated and 






























































Rapid light-controlled protein dimerization and reversal at multiple locations in 
living cells 
 To validate our protein dimerization strategy, we initially targeted mitochondria, 
which are highly dynamic, membrane-bound organelles involved in oxidative metabolism, 
apoptotic signaling, and other critical cellular pathways5,6. To test the ability of CTNH to 
recruit and reverse the induced recruitment of a freely diffusible protein to mitochondria, 
we localized haloenzyme to the cytosolic face of the mitochondrial outer membrane using 
the C-terminal domain of the Listeria monocytogenes ActA protein. HeLa cells 
expressing eDHFR fused to mCherry (mCherry–eDHFR) and ActA fused to GFP and 
haloenzyme (Halo-GFP-Mito) were incubated with 20 µM CTNH for 30 min, followed 
by a 30-min wash-out. No protein dimerization was observed prior to illumination, 
indicating that caging the TMP ligand with DEACM is sufficient to completely block 
binding between the TMP ligand and eDHFR (Figure 4.7A). Upon whole-field 
illumination with 444-nm light, rapid localization of mCherry-eDHFR was observed at 
the mitochondria (Figure 4.7A). The interaction between TMP and eDHFR is not 
covalent but, in steady state, the localization is persistent (Figure 4.7A and B). Upon 
illumination of the whole field of view with ~387 nm light, mCherry-eDHFR was 
released from mitochondria, indicating that protein dimerization was effectively 
deactivated by photocleavage of the NV linker (Figure 4.7A and B). To verify that the 
loss of mCherry from mitochondria was due to photocleavage but not photobleahing, we 
conducted a control experiment compared to the non-cleavable dimerizer TH that was 
previously published. Using the same laser condition, CTNH was photocleaved with 
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lower laser power (~5%) while TH was not affected (Figure 4.7E). Furthermore, to 
demonstrate spatiotemporal control, we used a targeted 405-nm laser to achieve spatially 
defined reversal of the dimerization in subcellular regions of the cell. After global 
activation of mitochondrial recruitment of mCherry-eDHFR, three regions of interest 
were targeted for sequential photocleavage of CTNH (Figure 4.7C and D).  
 Next, we targeted centromeres, chromosomal loci that play a crucial role in cell 
division7,8, by fusing haloenzyme tagged with GFP to the centromere protein CENP-B. 
HeLa cells expressing CENPB-GFP-Halo together with mCherry-eDHFR were treated 
with 20 µM CTNH for 30 min, subsequently washed, and exposed to a short pulse of 444 
nm light, leading to rapid recruitment of mCherry–eDHFR to centromeres within one 
second. Upon 387-nm illumination, this recruitment was rapidly reversed within one 
second (Figure 4.8A). Then, we used a targeted 405-nm laser to achieve rapid and 
spatially defined removal from an individual centromere (Figure 4.8A), demonstrating 
spatiotemporal control.  
 Finally, we targeted the plasma membrane, an important site for numerous cell 
signaling pathways9 where multiple biological phenomena have been studied using CID, 
including lipid signaling, Ras-regulated pathways, cell protrusion, and migration10-12 . To 
demonstrate the recruitment of mCherry-eDHFR to the plasma membrane using CTNH, 
we used HeLa cells expressing cytosolic mCherry-eDHFR and haloenzyme-GFP fused to 
the CAAX motif, a common plasma membrane targeting sequence, (where C is cysteine, 
A is an aliphatic amino acid and X is any amino acid). The C-terminus of CAAX proteins 
undergoes a series of post-translational modifications, resulting in cell membrane 
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localization13. As for mitochondria and centromeres, global recruitment of cytosolic 
mCherry-eDHFR was observed at the plasma membrane within one second upon 444-nm 
illumination and rapidly reversed upon 387-nm illumination (Figure 4.8B).  
 Together, these results indicate that a variety of subcellular locations, both 
cytosolic and nuclear, can be targeted to recruit and release a freely diffusive protein on 
the second timescale, which highlights the fast kinetics and spatial control of CTNH 
uncaging and cleavage using light. We foresee that CTNH will be widely applicable for 
rapid and reversible control of protein dimerization or localization at many different 
subcellular locations. Therefore, we applied this tool to control two highly dynamic 





















































































Figure 4.7 | Light-induced protein dimerization and reversal at mitochondria.  
Cells expressing Halo–GFP-ActA (mitochondria targeting sequence) and mCherry–eDHFR were 
treated with 20 µM CTNH for 30 min, followed by a 30-min washout, then illuminated with 444-nm 
light to uncage CTNH and recruit mCherry-eDHFR to mitochondria. (A-B) Whole-field illumination 
with ~387 nm UV light released mCherry from mitochondria. For quantification (b), mitochondrial 
mCherry intensity were normalized such that the minimum value observed over the course of 
experiment for each field is 0 and the maximum value is 1.   Each time point shows an average of 
10 fields. Error bars represent s.d. (C-D) The specified regions (1, 2, and 3, highlighted by orange, 
red, and pink dashed lines, respectively) were sequentially targeted for 405-nm laser illumination 
to cleave CTNH. For quantification (d), mitochondrial mCherry intensity in each region was 
divided by the maximum value observed over the course of experiment in that region. Scale bars, 
10 µm. (E) CTNH can be photocleaved whereas TH is not. Cells described above were treated 
with either 20 µM CTNH for 30 min, followed by a 30-min washout, or 0.1 µM TH (non-cleavable 
dimerizer) as indicated. Cells were illuminated with 444-nm light to uncage CTNH and recruit 
mCherry-eDHFR to mitochondria. After which the cells were illuminated again with 405-nm laser 
at different laser intensities. TH treated cells were illuminated with 405-nm laser under the same 
condition. The percentage of GFP and mCherry fluorescence intensities after 405-nm illumination 
were plotted as a function of 405-nm laser power. The loss of mCherry intensity as the 405-nm 
laser intensity increases to ~8% was due to photobleaching. However, the CTNH-treated cells 

































Figure 4.8 | Light-induced protein dimerization and the reversal at centromeres and plasma 
membrane. HeLa cells were expressing CenpB–GFP-Halo (for centromere targeting), CAAX-
GFP-Halo (for plasma membrane targeting), and cytosolic mCherry–eDHFR. (A) Cells were 
treated with 20 µM CTNH for 30 min, followed by 30-min washout prior to imaging. A 444-nm 
laser was used to activate the recruitment of mCherry-eDHFR to all centromeres within one 
second. Subsequently, a centromere (indicated by a yellow arrow) was targeted for 
spatiotemporal deactivation with a targetable 405-nm laser. The rapid photocleavage of CTNH 
resulted in reversal of the dimerization at the targeted centromere within one second.  (B) Cells 
described above were treated under the same condition. After 444-nm laser photoactivation for 
mCherry recruitment to plasma membrane, 387-nm illumination was used to reverse the 
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Reversible control of organelle transport within subcellular regions 
 Organelle transport is an essential biological process in eukaryotes and 
contributes to intracellular organization and cell polarity14. Various tools have been 
developed in order to probe functions of organelle positioning15,16, As a functional test for 
CTNH, we employed a previously reported peroxisome transport assay in living cells17,18. 
Peroxisomes are membrane-bound organelles that play a crucial role in the catabolism of 
fatty acids, reduction of reactive oxygen species, and biosynthesis of plasmalogens and 
ether phospholipids, and are critical for the normal function of mammalian brains and 
lungs19. Because peroxisomes are immobile under normal steady-state conditions, 
movement induced by light is easily observed, providing an ideal assay to test our new 
dimerizer. 
 To control peroxisome transport, we employed HeLa cells expressing PEX3-GFP-
Halo, a peroxisome-targeting sequence fused to GFP-haloenzyme, and KLC1-mCherry-
eDHFR, a fusion protein of mCherry-eDHFR linked to kinesin light chain 1 (KLC1) that 
binds and recruits kinesin heavy chain (Figure 4.9A). Prior to illumination, the 
peroxisomes spread throughout the cell, and KLC1-mCherry-eDHFR diffused in the 
cytosol (Figure 4.9B). After global activation of CTNH with a 444-nm laser, the 
peroxisomes were initially transported towards the plus ends of the microtubules at the 
cell periphery. Then, half of the cell was targeted for cleavage of CTNH with a 405-nm 
laser (Figure 4.9B, dashed yellow region). As a result, the induced peroxisome transport 
was disrupted in this region with no significant change in the peroxisome density after 
405-nm illumination and no accumulation of peroxisomes at the cell periphery (Figure 
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4.9B and C, regions 1 and 4). In contrast, peroxisome transport continued in the other 
half of the cell, which was not illuminated with the 405-nm laser, leading to a decrease in 
GFP intensity over time in the interior of this region and an increase at the periphery 
(Figure 4.9B and C, regions 2 and 3). At the cell periphery, the ratio of the GFP 
intensity in the uncleaved region to the cleaved region increased significantly after 405-
nm illumination, indicating that peroxisomes only accumulated in the uncleaved region 
(Figure 4.9D). Together, these results demonstrate that we can successfully employ light 






























Figure 4.9 | Controlling peroxisome transport with light.  
(A) Schematic and protein constructs. (B-D) HeLa cells expressing PEX3-GFP-Halo and KLC1-
mCherry-eDHFR were incubated with 20 µM CTNH for 30 min followed by a 30-min washout 
prior to imaging. CTNH was uncaged with 444-nm light at t = 0 min to recruit KLC1-mCherry-
eDHFR to peroxisomes. Half of the cell was illuminated with a 405-nm laser at t = 1 min to cleave 
CTNH and release KLC1 from peroxisomes. In a representative cell (b), dashed white and yellow 
lines indicate the cell outline and the photocleaved area, respectively, and brown square insets 
show KLC1 release from peroxisomes in the cleaved area. GFP intensity was quantified (c) in 
interior and peripheral regions in both the cleaved (regions 1 and 4) and uncleaved (regions 2 
and 3) areas. Intensity in each region over time was shown as a fraction of the maximal intensity 
observed in that region. The average GFP intensity (as a proxy for peroxisome intensity) at the 
cell periphery was quantified (d) as a ratio of region 3 to region 4, both before uncaging with 444-










dot represents an individual cell and the mean±sem was shown (n = 9 cells pooled from three 
independent experiments). ****P < 0.005, paired Student’s t-test. Scale bars, 10 µm. 
 
 
Activating and silencing mitotic checkpoint signaling 
 To achieve proper chromosome segregation in mitosis, the spindle checkpoint is 
initially activated until all chromosomes are properly attached to the spindle and then 
silenced at metaphase to allow the cell to progress to anaphase. For checkpoint proteins, 
localization to and release from kinetochores are essential steps in signal transduction that 
determine cell fate. With CTNH, we aimed to optically control both checkpoint activation 
and silencing by manipulating kinetochore localization of the checkpoint protein Mad1 
(Figure 4.10A). HeLa cells expressing Halo-GFP-SPC25, which localizes to 
kinetochores, and eDHFR-mCherry-Mad1 were incubated with CTNH. To demonstrate 
that the checkpoint can be re-activated with light, we targeted metaphase cells and 
recruited Mad1 from the cytosol to kinetochores using 444-nm light. As a result, <20% of 
cells with Mad1 recruited to kinetochores proceeded to anaphase within 30 min while 
>80% of control cells that were not exposed to 444-nm light proceeded to anaphase 
normally (Figure 4.10B and D). To show that the recruitment can be reversed by light, 
we globally recruited Mad1 to kinetochores and used 405-nm laser to cleave CTNH in 
some of the 444-nm light activated cells, and all the cells were followed for >30 min 
(Figure 4.10C). Without cleavage, Mad1 remained at kinetochores, and <10% of the 
cells proceeded to anaphase within 30 min, indicating that the mitotic checkpoint was 
active. In comparison, >60% of the cells in which Mad1 was released from the 
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kinetochores entered anaphase (Figure 4.10C and D). This re-activation20 and silencing 
of the mitotic checkpoint is consistent with our previous observations using a dimerizer 
that is not caged but can be photocleaved. However, with CTNH, both checkpoint 
activation and silencing can be controlled with light. These results demonstrate that we 






































Figure 4.10 | Activating and silencing the spindle assembly checkpoint.  
(A) Experimental design using CTNH for light-induced recruitment of Mad1 to and release from 
kinetochores. (B-D) HeLa cells expressing Halo-GFP-SPC25 and mCherry-eDHFR-Mad1 were 
incubated with 10 µM CTNH for 1 h followed by a 30-min washout. (B) Upon illumination with 










metaphase (left panel). Cells without Mad1 recruitment to metaphase kinetochores proceeded to 
anaphase normally (right panel). Brown square insets show the zoom-in regions in mCherry 
channel. (C) After global illumination with 444-nm light, Mad1 was released from kinetochores in 
some cells using a 405-nm laser to target the metaphase plate (c, right cell, yellow region), while 
other cells were not exposed to 405-nm light. Brown square insets show the zoom-in regions in 
mCherry channel of the left and right cell accordingly. (D) The percentage of cells entering 
anaphase within ~30 minutes after 444-nm uncaging in (b) and after 405-nm photocleavage in (c) 
was quantified for both cell populations. Error bars represent s.d. (number of cells in each 
condition, n = 15 for uncaged; n = 21 for caged; n = 20 for uncleaved; n = 25 for cleaved 


















Conclusions (Chapter 4) 
 In summary, we have developed a novel cell-permeable chemical inducer that can 
rapidly produce a discrete ON and then OFF state for spatiotemporal control of protein 
dimerization. Our results highlight the advantages of a hybrid chemical and genetic 
approach and of our modular design, which facilitates the development of new dimerizers 
with additional properties tailored for specific purposes. We demonstrate that many 
subcellular locations, such as plasma membrane, mitochondria, peroxisomes, centromeres 
and kinetochores, can be targeted with spatial precision for both recruitment and release 
of a cytosolic protein on a timescale of seconds. We demonstrated that peroxisome 
transport can be rapidly induced and disrupted on a subcellular length scale. Additionally, 
we applied this tool to manipulate kinetochore function by controlling mitotic checkpoint 
signaling. Our future goal is to use this dimerizer in conjunction with other orthogonal 
dimerizers to control multiple target proteins within a cell. This approach opens up a new 
avenue for a variety of biological studies, such as organelle transport, signal transduction, 
and cell division. We envision that our new chemical tool will be readily adopted to 
answer new biological questions that would be otherwise difficult to address with 













Concluding remarks and future directions 
 One of the biggest advantages of our system is the modular design that facilitates 
the opportunity to develop new dimerizers with additional properties on the same protein 
platform using light as an external control. Both Haloligand and TMP are biorthogonal in 
mammalian cells, providing minimal interference with biological pathways. The 
dimerization can be rapidly activated and reversed using a single pulse of light; therefore, 
sustained dimerization and its reversal can be achieved at high spatial and temporal 
resolution on a single-cell or sub-cellular levels. The wavelengths used for photo-
activation are non-invasive and suitable with common excitation wavelengths for 
imaging such as GFP and mCherry. To the best of our knowledge, CTNH is the most 
advanced dimerizer that has been reported. We demonstrate that our new optogenetic 
tools are applicable to reversibly controlled highly dynamic processes such as 
peroxisome transport and mitotic checkpoint signaling. We envision that our new tools 
will be readily adapted for studying many other biological events, such as apoptosis, 
autophagy, cell cycle, gene regulations, stem cell differentiation, enzyme activities, and 
numerous cell signaling pathways including in cancer and other diseases. 
 Our current efforts are to expand the CID toolkits based on our system. We are 
developing new molecules with functionally diverse properties, which highlight the 
power of our modular design (unpublished, Figure 4.11). HaloTag can be replaced by 
another widely utilized covalent protein labeling system called SNAP-Tag. We have 
synthesized non-caged TMP-SNAP, TS (10) and tested in a live cell assay (unpublished). 
10 could globally induced eDHFR and SNAP fusion proteins as TH (1). We then 
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developed the photocaged analogs NVOC-TMP-SNAP, NTS (11) and NVOC-TMP-
SNAPCl, NTSCl (12) but surprisingly, 11 failed to induce dimerization while 12 is not as 
cell-permeable as its counterpart NTH (2).  
Furthermore, protein molecules can interact to form a physiologically active 
ternary complex. For example, the Silent Information Regulators (SIR) Sir2p, Sir3p, and 
Sir4p assemble to form a heterotrimeric protein complex that is required for gene 
silencing at telomeres. Conversely, Sir2p alone forms a homotrimeric histone deacetylase 
that is required for rDNA repression. The ability to simultaneously control the interaction 
of three different proteins at a specific subcellular location will allow us to further 
investigate and gain insight into more complex biological networks with the 
complementary protein dimerization techniques. To date, there have not been reports of a 
chemical tool that is able to accomplish this process; therefore, we envision that our CID 
system could be tethered with the third ligand to previous dimerizers, we can create a 
new platform for chemically-induced trimerization (CIT). We have synthesized the non-
caged tri-TMP-Halo-SNAP, tTHS (13), tri-TMP-Halo-SNAPCl, tTHSCl (14), and the 
caged TMP tri-NVOC-TMP-Halo-SNAPCl, tNTHSCl (15) (Figure 4.11). Unfortunately, 
our preliminary results showed that these molecules were not cell-permeable enough to 
be useful, likely due to the high molecular weights. Further investigations and structural 
modifications are necessary to improve these molecules. 
 Finally, by attaching the SNAP ligand to the cage of NTH, SNAPCl-NVOC-
TMP-Halo, SNTH (16) is synthesized which is able to swap dimerized protein for a 
different protein upon illumination. This novel swappable protein dimerizer is an exciting 
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tool by itself and can be combined with existing complementary tools for studying 
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General information for chemistry 
 
All commercially available reagents and solvents were used as received. All 
chemicals were purchased from Sigma Aldrich and Fisher Scientific, unless otherwise 
specifically noted. Boc-anhydride, 7-(Diethylamino)-4-(methyl)coumarin, CDI, and 
NaBH4 were purchased from Chem-Impex International. 2-(2-aminoethoxy)ethanol, NaH 
(60% in mineral oil), and 48% aq.HBr, tetraethylene glycol, fuming nitric acid, succinic 
anhydride, DMAP, and DBU were purchased from Acros Organics. 4-Nitrophenyl 
chloroformate was purchased from Alfa Aesar. 6-Chloro-1-iodohexane, 4,5-dimethoxy-2-
nitrobenzyl chloroformate (NVOC) were purchased from both Sigma Aldrich and Fisher. 
6-Bromo-1-chlorohexane and vanillin were purchased from TCI America. Tert-butyl-3-
iodopropylcarbamate was purchased from Ace Synthesis LLC. Trimethoprim was 
purchased from Astatech, Inc, and Chem-Impex International. HATU was purchased 
from GenScript and Oakwood Chemical. Selenium dioxide and CBr4 were purchased 










• Thin-layer chromatography was performed on Sorbent Technologies silica plates 
(250 µm thickness).  
• Silica gel column chromatography was performed using Silicycle silica gel 
(55−65 Å pore diameter) by manual and an automated system. Automated flash 
column chromatography was performed using RediSep Rf silica gel on 
CombiFlash Rf+ system with internal UV detector and also evaporative light 
scattering detector (ELSD). The instrument was purchased from Teledyne Isco, 
Inc., NE., USA. Generous technical support is with the help from Constance D. 
Reber, the sale representative. 
• High-performance liquid chromatography (HPLC) was performed for most of the 
final product purification using a JASCO PU-2080 Plus Intelligent HPLC Pump 
and Phenomenex Luna C18 columns (5 µm particle size, 100 Å pore size). HPLC-
grade water with 0.1% TFA added and acetonitrile are commonly used for 
gradient elution but water with TFA is also used in some cases. 
• Infrared (IR) spectra were obtained on Jasco FT-IR Spectrum BX system and 
reported as wavenumber of the absorption maxima between 4000 cm-1 and 800 
cm-1 of only major peaks.  
• Ultraviolet-visible absorption spectrophotometry was performed on a JASCO V-
650 spectrophotometer with a PAC-743R multichannel Peltier using quartz cells 
with a 1 cm cell path length.  
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• Proton nuclear magnetic resonance spectroscopy (1H NMR) and Carbon nuclear 
magnetic resonance spectroscopy (13C NMR) spectra were recorded on a Bruker 
UNI400, AVII 500, and BioDRX 600 NMR (for most 2D NMR experiments) 
with the support from NMR facility directors; Dr. George Furst and Dr. Jun Gu. 
• Low-resolution mass spectrometry (LCMS) or nominal mass accuracy. A walk-up 
LCMS machine was used to obtain data. The instrument model: Waters Acquity 
UPLC system equipped with a Waters TUV detector (254 nm) and a Waters SQD 
single quadrupole mass analyzer with electrospray ionization (ESI).  LC gradient 
500 uL/min: 30 second hold 95:5 (water:acetonitrile 0.1% v/v formic acid), 2 
minute gradient to 5:95, and 30 second hold. Acquity UPLC BEH C18, 1.7um, 
2.1x 50 mm column. Diode-array detector for dual wavelength of 254 nm and 330 
nm detection was also used in the instrument. 
• High-resolution mass spectrometry (HRMS) were obtained at the University of 
Pennsylvania’s Mass Spectrometry Service Center with the support from the 
former mass spectrometry facility director, Dr. Rakesh Kohli on a Micromass 
AutoSpec electrospray/chemical ionization spectrometer. An upgraded system 
supported by the new director, Dr. Charles W. Ross III., for accurate mass 
measurement analyses were conducted on either a Waters GCT Premier, time-of-
flight (TOF), GCMS with electron ionization (EI), or an LCT Premier XE, TOF, 
LCMS with electrospray ionization (ESI).  Samples were taken up in a suitable 
solvent for analysis.  The signals were mass measured against an internal lock 
mass reference of perfluorotributylamine (PFTBA) for EI-GCMS, and leucine 
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enkephalin for ESI-LCMS.  Waters software calibrates the instruments, and 
reports measurements, by use of neutral atomic masses. The mass of the electron 
is not included. 
 
Synthesis Notes 
• All syntheses were done in the dark room with some Red LED Strip light (650 
nm) to prevent all light-sensitive compounds from accidental exposure to light 
and decomposition of the compounds. 
• Reactions are typically done under inert atmosphere (argon or nitrogen) 
• All solvent mixtures used in the synthesis and purification as well as TLC solvent 
are prepared as volume percent (v/v %). 
• Room temperature (rt) is normally controlled to be at 25 oC  











Synthesis details for Scheme 2.1 
  




19 was first synthesized following the precedent of Singh et. al1. To a solution of 
2-(2-aminoethoxy)ethanol 18 in anhydrous EtOH was added Boc2O at 0 °C. After stirring 
at room temperature (rt) for 2 h, the reaction mixture was evaporated. The product was 
then extracted with DCM and the combined organic layers were dried over Na2SO4 and 
evaporated under vacuum to obtain the product 19 as colorless oil in quantitative yield, 
which was used for the next step without further purification. The spectral data were in 
agreement with the reported data1. 
To a solution of 19 in a 2:1 mixture of THF and DMF at 0 °C was added NaH 
(60% in mineral oil). After stirring at 0 °C for 30 min, 6-chloro-1-iodohexane was added 
to the above solution. The reaction mixture was stirred overnight (16 h) and quenched 
with saturated NH4Cl. The mixture was extracted with EtOAc, washed with H2O and 
brine. The combined organic layers were dried over Na2SO4 and concentrated. The crude 
product was purified by silica gel column chromatography using EtOAc:Hexanes (20% 
to 30%) to yield pure product 20 (49%) as colorless oil. The spectral data were in 
agreement with the reported data1. 
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Compound 21 was synthesized by modification of a procedure described by 
Passemard et al2.  To a solution of 20 (1.0 g, 3.21 mmol) in 10 mL anhydrous DCM at        
0 °C was slowly added TFA (10 mL, 130 mmol). Thereafter the reaction mixture was 
warmed to rt and stirred for 2 h. After completion of the reaction as evident by TLC 
analysis, the solvent was removed under high vacuum to obtain the crude deprotected 
product as a TFA salt, which was used without further purification.  
To a solution of the above deprotected product (0.72 g, 3.21 mmol) in DCM (5 mL) 
was slowly added triethylamine (19.26 mmol, 1.95 g) and subsequently succinic anhydride 
(9.63 mmol, 0.96 g) followed by stirring overnight (16 h) at 25°C. Next, the reaction 
mixture was washed with 1 M aq. HCl (3×5 mL) followed by brine. The organic layer was 
dried over MgSO4 and concentrated under vacuum to afford 21 as a brown oil (90% in two 
steps).  
Rf = 0.45 (5% MeOH:DCM).  
IR (NaCl, thin film): ν 3320, 2936, 2865, 1733, 1653, 1558, 1436, 1172, 1116 cm-1.  
1H NMR (500 MHz, CDCl3) δ ppm: 6.47 (s, 1H), 3.65 - 3.58 (m, 4H), 3.58 - 3.41 
(m, 8H), 2.70-2.63 (m, 2H), 2.52 (dd, J = 7.5, 5.8 Hz, 2H), 1.77 (m, 6.8 Hz, 2H), 1.68 -
1.52 (m, 2H), 1.50 - 1.41 (m, 2H), 1.41 - 1.31 (m, 2H).  
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13C NMR (126 MHz, CDCl3) δ ppm: 175.3, 172.5, 77.4, 71.5, 70.2, 70.2, 69.7, 
45.2, 39.6, 32.6, 31.3, 30.3, 26.8, 25.4.  
HRMS (ESI, m/z): Calcd. for C14H26ClNO5 [M+Na]+: 346.1397. Found: 
346.1400. 
 
The known compounds, 22 and 23, can be synthesized following the literature 
precedent3. 
 
Synthesis of tert-butyl (3-(4-((2,4-diaminopyrimidin-5-yl)methyl)-2,6-dimethoxyphe-




The known compound 24 was synthesized following Jing et al4.  
Compound 24, tert-butyl N-(3-iodopropyl)carbamate, and cesium carbonate were 
dissolved in anhydrous DMF. The reaction mixture was heated at 70 °C for 7 h, followed 
by the removal of solvent under high vacuum. The crude mixture was purified by column 
chromatography with silica gel MeOH:DCM (10%, v/v)  to yield product 25 as a brown 
amorphous solid (42%) The spectral data were in agreement with the reported data4.  
Rf = 0.70 (20% MeOH:DCM).  
UV-Vis (λmax in DCM): 239, 282 nm.  
IR (NaCl, thin film): ν 3338, 1620, 1506, 1456, 1242, 1124 cm-1. 
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1H NMR (500 MHz, MeOD) δ ppm: 7.51 (s, 1H), 6.51 (s, 2H), 3.94 (t, J = 5.9 
Hz, 2H), 3.78 (s, 6H), 3.63 (s, 2H), 3.28 (d, J = 6.7 Hz, 2H), 1.88 - 1.76 (m, 2H), 1.43 (s, 
9H).  
13C NMR (126 MHz, MeOD) δ ppm: 164.3, 163.1, 158.4, 155.9, 154.6, 
136.4, 108.0, 106.6, 80.0, 72.3, 56.5, 39.1, 39.0, 34.4, 30.8, 28.8.  
HRMS (ESI, m/z): Calcd. for C21H31N5O5 [M+H]+:434.2403. Found: 434.2413. 
 






Reaction conditions were adapted from Wysocki et al5. To a stirring solution of 
compound 25 (0.63 g, 1.45 mmol) and 1 equiv. of DIEA (0.188 g, 1.45 mmol) in DCM 
was added 4,5-dimethoxy-2-nitrobenzyl chloroformate (NVOC) (0.40 g, 1.45 mmol) in 
the dark. The mixture was stirred at room temperature overnight (16 h). The mixture was 
washed with H2O and brine. The combined organic layers were dried over Na2SO4 and 
concentrated under vacuum. The crude product was purified by silica gel column 
chromatography using MeOH:DCM (1% to 5%) to yield pure product 26 (41%) as a 
yellowish semi-solid material.  
Rf = 0.50 (5% MeOH:DCM).  
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UV-Vis (λmax in DCM): 239, 282, 346 nm.  
IR (NaCl, thin film): ν 3375, 2937, 1699, 1589, 1522, 1460, 1331, 1277, 1221, 
1172, 1126, 1072, 914, 731 cm-1.  
1H NMR (500 MHz, DMSO-d6) δ ppm: 10.02 (s, 1H), 7.78 (s, 1H), 7.72 (s, 1H), 
7.45 (s, 1H), 6.74 (d, J = 5.7 Hz, 1H), 6.66 (s, 2H), 6.60 (s, 2H), 5.43 (s, 2H), 3.91 (s, 
3H), 3.87 (s, 3H), 3.80 (t, J = 6.3 Hz, 2H), 3.72 (s, 6H), 3.63 (s, 2H), 3.09 (q, J = 6.6 Hz, 
2H), 1.70 (t, J = 6.7 Hz, 2H), 1.37 (s, 9H).  
13C NMR (126 MHz, DMSO-d6) δ ppm: 162.4, 155.9, 155.6, 153.6, 152.9, 151.6, 
138.9, 134.8, 134.6, 127.8, 111.7, 110.4, 108.1, 106.0, 77. 5, 70.5, 62.7, 56.4, 55.9, 55.9, 
39.1, 37.4, 32.9, 30.0, 28.3.  
HRMS (ESI, m/z): Calcd. for C31H40N6O11 [M+H]+: 673.2833. Found: 673.2835. 
 
Synthesis of N1-(2-(2-((6-chlorohexyl)oxy)ethoxy)ethyl)-N4-(3-(4-((2,4-diaminopyri-




Compound 25 (60 mg, 0.138 mmol) was deprotected by directly dissolving in 4 
mL 50% TFA:DCM and stirring at room temperature for 2 h. Next, excess TFA was 
removed under high vacuum to yield the TFA salt as a colorless solid. Rf = 0.02 in 10% 
MeOH:DCM. The crude product was used in the next step without further purification. 
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The crude mixture above was dissolved in 1 mL of DMF followed by addition of 
DIEA (17.9 mg, 25 µL, 0.138 mmol). After stirring for 10 minutes, a 1-mL solution of 21 
(45 mg, 0.138 mmol) in DMF, DIEA (17.9 mg, 25 µL, 0.138 mmol), and HATU (52.6 
mg, 0.138 mmol) was added to the crude mixture. The mixture was then allowed to stir 
for another 2 h before being concentrated under high vacuum. The crude mixture was 
purified by silica gel column chromatography using 3% MeOH:DCM to yield pure 
product 1 (69%) as a brown oil.  
Rf = 0.55 (5% MeOH:DCM).  
UV-Vis (λmax in DCM): 210, 288 nm.  
IR (NaCl, thin film): ν 3337, 2936, 1657, 1558, 1505, 1457, 1232, 1125 cm-1.  
1H NMR (500 MHz, CDCl3) δ ppm : 7.57 (s, 1H), 7.06 (t, J = 5.8 Hz, 1H), 6.62 
(d, J = 6.3 Hz, 1H), 6.38 (s, 2H), 5.58 (s, 2H), 5.40 (s, 2H), 4.01 (t, J = 5.5 Hz, 2H), 3.79 
(s, 6H), 3.67 - 3.25 (m, 22H), 2.50 (s, 4H), 1.87 (p, J = 5.7 Hz, 2H), 1.81 - 1.69 (m, 2H), 
1.59 (p, J = 6.9 Hz, 2H), 1.49 - 1.39 (m, 2H), 1.39 - 1.29 (m, 2H).  
13C NMR (126 MHz, CDCl3) δ ppm: 172.4, 172.0, 163.2, 153.6, 135.6, 133.6, 
107.1, 105.3, 77.4, 72.4, 71.4, 70.4, 70.1, 69.9, 56.3, 45.2, 39.4, 38.0, 34.6, 32.6, 31.9, 
31.8, 29.5, 29.3, 26.8, 25.5.  










Compound 26 was deprotected and reacted with compound 21 using the same 
procedure for 1 as mentioned above. The crude mixture of product 2 was purified by 
silica gel column chromatography using 1% MeOH:DCM to yield pure product 2 (70%) 
as brown oil.  
Rf = 0.45 (5% MeOH:DCM).  
UV-Vis (λmax in DCM): 238, 280, 340 nm.  
IR (NaCl, thin film): ν 3417, 3359, 3149, 2939, 1726, 1647, 1624, 1585, 1520, 
1466, 1325, 1271, 1250, 1223, 1124, 1070, 984, 912, 839, 729 cm-1. 
1H NMR (500 MHz, DMSO-d6) δ ppm: 9.97 (s, 1H), 7.83 (t, J = 5.7 Hz, 1H), 
7.78 (s, 1H), 7.73 (d, J = 10.2 Hz, 2H), 7.45 (s, 1H), 6.61 (d, J = 15.9 Hz, 4H), 5.43 (s, 
2H), 3.92 (s, 2H), 3.87 (s, 2H), 3.82 (t, J = 6.3 Hz, 2H), 3.72 (s, 6H), 3.61 (dd, J = 14.8, 
8.2 Hz, 4H), 3.53 - 3.42 (m, 6H), 3.37 (m, 6.2 Hz, 4H), 3.30 (s, 2H), 3.23 - 3.12 (m, 4H), 
2.29 (m, 4H), 1.70 (m, 4H), 1.47 (m, 2H), 1.42 - 1.19 (m, 8H). 
13C NMR (126 MHz, DMSO-d6) δ ppm: 171.4, 171.1, 162.3, 155.8, 154.9, 153.6, 
152.9, 151.5, 147.6, 138.9, 134.9, 134.5, 127.7, 111.7, 110.5, 108.1, 106.1, 70.4, 70.1, 
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69.5, 69.4, 69.1, 62.6, 56.4, 56.1, 55.9, 45.3, 38.5, 35.9, 32.9, 32.0, 30.8, 30.8, 29.8, 29.0, 
29.0, 26.1, 24.9.  

















Synthesis details for Scheme 3.2 
 
Compounds 21 was synthesized as described previously. 
 




Compound 29 was synthesized following a modified procedure described by 
Schönleber et al6. 
Selenium dioxide (3.33 g, 30.0 mmol) was added to a solution of commercially 
available 4-methyl-7-diethylaminocoumarin (4.63 g, 20.0 mmol) in p-xylene (120 mL), 
and heated to reflux under inert atmosphere with vigorous stirring. After 24 h, the 
mixture was cooled down to room temperature (rt) and added additional selenium dioxide 
(1.50 g, 13.5 mmol). The crude mixture was continued refluxing for another 48 h. After 
refluxing for 3 days, the crude black mixture was filtered through celite and silica gel 
followed by concentration under reduced pressure at 50 °C. The dark brown residual oil 
was redissolved in EtOH:THF (1:1, 130 mL) in a 500 mL round-bottom flask, sodium 
borohydride (760 mg, 20.0 mmol) was added portionwise while stirring, and the solution 





hydrolyzed with 1 M HCl (20 mL) and diluted with H2O (50 mL). The organic solvents 
(EtOH and THF) were partially removed under reduced pressure before the aqueous 
solution was extracted with DCM (3×100 mL). The organic phase was washed with H2O 
and brine, dried over MgSO4, and then concentrated in vacuo. The resulting crude 
mixture was purified by column chromatography (Acetone:DCM, 1:5) to obtain 494 mg 
(10% over two steps) of the alcohol product as a dark yellow semi-solid.  The spectral 
data were in agreement with the reported data6. 
Rf = 0.30 (5% MeOH:DCM).  
1H NMR (500 MHz, Chloroform-d): 7.27 (d, J = 9.0 Hz, 1H), 6.51 (dd, J = 9.0, 
2.6 Hz, 1H), 6.39 (d, J = 2.6 Hz, 1H), 6.25 (t, J = 1.4 Hz, 1H), 4.80 - 4.76 (m, 2H), 3.75 - 
3.71 (m, 1H), 3.34 (q, J = 7.1 Hz, 4H), 1.15 (t, J = 7.1 Hz, 6H).  
13C NMR (126 MHz, Chloroform-d): 163.2, 156.0, 155.8, 150.6, 124.5, 108.8, 
106.4, 105.1, 97.6, 60.7, 44.7, 12.5. 
LCMS (ESI, m/z): Calcd. for C14H18NO3  [M+H]+: 248.13. Found: 248.27. 
 
 Synthesis of tert-butyl (3-(4-((2,4-diaminopyrimidin-5-yl)methyl)-2,6-dimethoxy-
phenoxy)propyl)carbamate,  TMP-NBoc (25)   
 
 









Compound 24, TMP-OH (4.14 g, 15.0 mmol) was dissolved in DMSO (45 mL) 
and DBU (2.51 g, 16.5 mmol) was added at room temperature (rt). After TMP-OH was 
completely dissolved and the solution turned deep red after about 10 minutes, tert-butyl-
3-bromopropylcarbamate (3.93 g, 16.5 mmol) was added. The reaction mixture was 
stirred at rt overnight. Distilled water (150 mL) was added and the mixture was extracted 
with EtOAc (4×100 mL). The combined EtOAc solution was washed with water (100 
mL) and brine, dried over MgSO4, and evaporated. The crude mixture was purified by 
column chromatography with silica gel (10% to 20% MeOH:DCM) to yield 3.67 g (56%) 
of product 25 as light brown amorphous  solid. The spectral data were in agreement with 
the reported data7.  
Rf = 0.70 (20% MeOH:DCM).  
UV-Vis (λmax in DCM) : 239, 282 nm.  
1H NMR (500 MHz, MeOD): 7.51 (s, 1H), 6.51 (s, 2H), 3.94 (t, J = 5.9 Hz, 2H), 
3.78 (s, 6H), 3.63 (s, 2H), 3.28 (d, J = 6.7 Hz, 2H), 1.88 - 1.76 (m, 2H), 1.43 (s, 9H).  
13C NMR (126 MHz, MeOD): 164.3, 163.1, 158.4, 155.9, 154.6, 136.4, 108.0, 
106.6, 80.0, 72.3, 56.5, 39.1, 39.0, 34.4, 30.8, 28.8.  





Synthesis of tert-butyl (3-(4-((4-amino-2-((((7-(diethylamino)-2-oxo-2H-chromen-4-yl)-
methoxy)carbonyl)amino)pyrimidin-5-yl)methyl)-2,6-dimethoxyphenoxy)propyl)- 




 In a 50-mL round-bottom flask equipped with nitrogen, compound 25 (315 mg, 
0.730 mmol) was dissolved in anhydrous and degassed DCM (5 mL), DIEA (150 µL, 
0.730 mmol), DMAP (45 mg, 0.36 mmol). The resulting light brown suspension was 
stirred for 15 minutes at room temperature (RT). After the mixture became less cloudy, 
1,1′-Carbonyldiimidazole (177 mg, 1.09 mmol, CDI, ≥98% purity, purchased from Chem 
Impex Int, Inc. and kept dried in a desiccator) was added to the mixture. Thereafter, the 
suspension was heated to reflux and the solution became transparent. Heating was 
continued to reflux, under nitrogen atmosphere, overnight. The reaction mixture was then 
cooled to rt. The reaction progression was monitored by LCMS as follows: a small 
amount of the solution was taken, dissolved in ~500 µL of MeOH, injected on LCMS 
(Waters, ESI+ mode). The formation of CDI-TMP-NBoc could be observed as a MeOH 
adduct of MeOH-trapped CDI-TMP-NBoc intermediate, [M+H+]: 550.24, the structure 



























 In a separate small vial, Coumarin-OH, compound 29 (180 mg, 0.730 mmol), was 
dissolved in DCM (2 mL), DIEA (150 µL, 0.730 mmol), DMAP (45 mg, 0.36 mmol) and 
then added into the above solution. Subsequently, the mixture was heated to reflux 
overnight and reaction progression was monitored by TLC and LCMS. A small amount 
of the solution was taken, dissolved in ~500 µL of MeOH, injected on LCMS (Waters, 
ESI+ mode) for analysis. The addition of one Coumarin-OH was observed with two 
isomers. However, the major isomer was Coumarin-TMP-NBoc, 30, LCMS (ESI+) 
[M+H+]: 707.33. The reaction mixture was then cooled to rt, quenched with H2O (20 
mL), and diluted with DCM (30 mL) and separated. The organic layer was washed with 
saturated aqueous solution of NH4Cl once and then brine, dried with anhydrous Na2SO4, 
concentrated to get dark brown oil. The crude mixture was purified by column 
chromatography with silica gel (2% to 20% MeOH:DCM) to yield 60 mg (12% over two 
steps) of product 30 as dark brown amorphous solid.  
 Rf = 0.40 (10% MeOH:DCM).  
 UV-Vis (λmax in 20% DMSO/PBS buffer pH 7.4): 239, 282, 381 nm.  
 IR (NaCl, thin film): ν 3309, 2934, 1717, 1605, 1527, 1506, 1424, 1356, 1206, 
1126 cm-1.  
 1H NMR (500 MHz, DMSO-d6): 9.99 (s, 1H), 7.80 (s, 1H), 7.47 (d, J = 9.0 Hz, 
1H), 6.78 - 6.51 (m, 7H), 6.19 (d, J = 1.5 Hz, 1H), 5.30 (d, J = 1.5 Hz, 2H), 3.81 (t, J = 
6.3 Hz, 2H), 3.72 (s, 6H), 3.64 (s, 2H), 3.43 (q, J = 7.0 Hz, 4H), 3.09 (q, J = 6.5 Hz, 2H), 
1.70 (p, J = 6.6 Hz, 2H), 1.37 (s, 9H), 1.12 (t, J = 7.0 Hz, 6H).  
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 13C NMR (126 MHz, DMSO-d6): 155.7, 155.5, 155.0, 152.8, 151.4, 150.4, 134.5, 
125.3, 111.8, 108.7, 106.0, 105.2, 104.6, 96.8, 77.4, 70.5, 61.1, 55.9, 44.0, 39.1, 37.32, 
32.9, 30.0, 28.2, 12.3.  








Compound 30 (60 mg, 0.085 mmol) was deprotected by directly dissolving in 2 
mL of TFA:DCM (1:3) and stirring at room temperature (rt) for 2 h. Next, excess TFA 
was removed and co-evaporated with DCM and DMF several times under high vacuum 
to yield the TFA salt as a light brown semi-solid. Rf = 0.02 in 10% MeOH:DCM. The 
primary amine salt can be stained on TLC using Ninhydrin solution, a pink spot close to 
baseline appeared upon heated. The crude product was used in the next step without 
further purification. 
The crude mixture above was dissolved in 1 mL of DMF followed by addition of 


















mL solution of 21 (28 mg, 0.085 mmol) in DMF, DIEA (~200 µL), and HATU (65 mg, 
0.17 mmol) were stirred at rt for 10 minutes and then added to the above stirring mixture 
of the deprotected Coumarin-TMP-NH2 TFA salt. The mixture was then allowed to stir at 
rt for another 16 h before being concentrated under high vacuum. The crude brown oil 
was dissolved in DCM (50 mL) and washed with saturated NH4Cl solution and brine, 
dried with anhydrous Na2SO4, and concentrated under reduced pressure. The crude 
mixture was purified by silica gel column chromatography using 2% to 15% 
MeOH:DCM to yield pure product 5 (64% over two steps) as a brown oil.  
Rf = 0.40 (10% MeOH:DCM).  
UV-Vis (λmax in 20% DMSO/PBS buffer pH 7.4): 238, 280, 381 nm.  
1H NMR (500 MHz, DMSO-d6): 10.03 (s, 1H), 7.85 (t, J = 5.6 Hz, 1H), 7.81 - 
7.72 (m, 2H), 7.44 (d, J = 9.0 Hz, 1H), 6.66 (m, 3H), 6.58 (s, 2H), 6.52 (d, J = 2.5 Hz, 
1H), 6.17 (d, J = 1.4 Hz, 1H), 5.28 (d, J = 1.5 Hz, 2H), 3.80 (t, J = 6.3 Hz, 2H), 3.70 (s, 
6H), 3.64 - 3.55 (m, 4H), 3.50 - 3.28 (m, 14H), 3.16 (m, 4H), 2.27 (m, 4H), 1.67 (m, 4H), 
1.50 - 1.40 (m, 2H), 1.38 - 1.22 (m, 4H), 1.09 (t, J = 7.0 Hz, 6H).  
13C NMR (126 MHz, DMSO-d6): 171.4, 171.2, 162.4, 160.8, 155.8, 155.7, 155.0, 
152.91, 151.5, 150.4, 134.5, 125.3, 108.7, 106.0, 105.2, 104.6, 96.9, 70.5, 70.2, 69.6, 
69.4, 69.1, 61.1, 55.9, 45.4, 44.0, 39.3, 38.6, 35.9, 32.9, 32.0, 30.9, 30.8, 29.8, 29.1, 26.1, 
24.9, 12.3.   
HRMS (ESI, m/z): Calcd. for C45H63ClN7O11 [M+H]+: 912.4274 Found: 
912.4276 
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Synthesis details for Scheme 3.3 
 Compound 31 – 38 (except compound 36) were synthesized using modified 
procedures reported by Erhart et al8 and Zimmermann et al9. 
 
Synthesis of 18-chloro-3,6,9,12-tetraoxaoctadecan-1-ol, 4EG-Halo (32) 
 
 
Tetraethyleneglycol, 4EG, 31 (1.45 mL, 8.40 mmol) was dissolved in 18 mL of 
THF:DMF (2:1). Sodium hydride (60% in mineral oil, 368 mg, 9.20 mmol) was added 
portionwise at 0 °C. After stirring for 30 min at room temperature (rt), 1-bromo-6-
chlorohexane (1.25 mL, 8.40 mmol) was added dropwise. The mixture was stirred at rt 
for 16 h. The excess of sodium hydride was carefully quenched with water and the crude 
mixture was poured into H2O (50 mL) and extracted with EtOAc (3×50 mL). The 
combined organic layers were dried over Na2SO4 and concentrated under reduced 
pressure. The crude oil was purified by flash column chromatography using 2% to 5% 
MeOH:DCM to yield compound 32 as a light yellow oil (1.05 g, 40%). The spectral data 
were in agreement with the reported data8. 
Rf = 0.55 (5% MeOH:DCM). 
HO O O O O Cl
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1H NMR (500 MHz, Chloroform-d): 3.72 (t, J = 4.5 Hz, 2H), 3.69 - 3.55 (m, 
14H), 3.53 (t, J = 6.7 Hz, 2H), 3.45 (t, J = 6.6 Hz, 2H), 2.67 (s, 1H), 1.77 (p, J = 6.9 Hz, 
2H), 1.59 (p, J = 6.9 Hz, 2H), 1.49 - 1.31 (m, 4H).  
13C NMR (126 MHz, Chloroform-d): 72.7, 71.4, 70.8, 70.7, 70.7, 70.7, 70.5, 
70.2, 61.9, 45.2, 32.7, 29.6, 26.8, 25.5. 
HRMS (ESI, m/z): Calcd. for C14H30ClO5 [M+H]+: 313.1782 Found: 313.1783 
 
Synthesis of 1-bromo-18-chloro-3,6,9,12-tetraoxaoctadecane, Br-4EG-Halo (33) 
 
 
Compound 32 (2.10 g, 6.71 mmol) was dissolved in THF (20 mL). 
Triphenylphosphine (2.05 g, 7.82 mmol) and carbon tetrabromide (2.59 g, 7.82 mmol) 
were added portionwise at 0°C. The resulting mixture was stirred at room temperature (rt) 
for 16 h. The solvent was evaporated under reduced pressure and the crude oil was 
purified by flash column chromatography using 10% to 50% EtOAc:Hexanes to yield 
compound 33 as a light yellow oil (1.24 g, 50%). The spectral data were in agreement 
with the reported data8.  
Rf = 0.60 (40% EtOAc:Hexanes).  
Br O O O O Cl
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1H NMR (500 MHz, Chloroform-d): 3.80 (t, J = 6.3 Hz, 2H), 3.68 - 3.61 (m, 
10H), 3.59 - 3.55 (m, 2H), 3.52 (t, J = 6.7 Hz, 2H), 3.46 (q, J = 6.5 Hz, 4H), 1.77 (m, 
2H), 1.59 (m, 2H), 1.49 - 1.30 (m, 4H).  
13C NMR (126 MHz, Chloroform-d): 71.4, 70.8, 70.8, 70.8, 70.7, 70.7, 70.3, 
45.2, 32.7, 30.4, 29.6, 26.8, 25.6.   
HRMS (ESI, m/z): Calcd. for C14H29BrClO4 [M+H]+: 375.0938 Found: 375.0939 
Synthesis of 4-(benzyloxy)-3-methoxybenzaldehyde (35) 
 
 
Compound 35 was synthesized using the same procedure described by Critchley 
et al10. In brief, commercially available vanillin 34 (10.0 g, 65.7 mmol) and 
benzylbromide (11.2 g, 65.7 mmol) were dissolved in 100 mL of DMF. K2CO3 (9.08 g, 
65.7 mmol) was added and the mixture was stirred at 80°C for 16 h. The reaction was 
concentrated under high vacuum, quenched with saturated NH4Cl (500 mL) and extracted 
with EtOAc three times. The combined organic layers were dried over Na2SO4 and 
concentrated under reduced pressure. The resulting product 35 (15.76 g, 99%) was used 
without further purification. The spectral data were in agreement with the reported data10.  
Rf = 0.60 (25% EtOAc:Hexanes).  
1H NMR (500 MHz, Chloroform-d): 9.84 (s, 1H), 7.44 (m, 3H), 7.41 - 7.36 (m, 






13C NMR (126 MHz, Chloroform-d): 191.1, 153.7, 150.2, 136.1, 130.4, 128.7, 
128.3, 127.3, 126.8, 112.5, 109.4, 71.0, 56.2. 
HRMS (ESI, m/z): Calcd. for C15H15O3 [M+H]+: 243.1021 Found: 243.1018 
 
Synthesis of 4-(benzyloxy)-5-methoxy-2-nitrobenzaldehyde (35a) 
 
 
Compound 35a was synthesized using the same procedure described by Critchley 
et al10. In brief, the benzylated vanillin 35 (1.00 g, 4.13 mmol) and 1,2-dichloroethane (5 
mL) were cooled to -30 °C under argon. Fuming nitric acid (highly corrosive) (2 mL) 
was added dropwise with caution, and the temperature was maintained at -15 °C for 
3 h (with proper shielding equipment in a fume hood). Thereafter, the reaction 
mixture was poured into ice-water and extracted with EtOAc three times. Removal of the 
solvent gave a bright yellow amorphous solid, which was used in the next step without 
further purification. 
Rf = 0.50 (25% EtOAc:Hexanes).  
1H NMR (500 MHz, Chloroform-d): 10.44 (s, 1H), 7.67 (s, 1H), 7.48 -7.31 (m, 
6H), 5.27 (s, 2H), 4.02 (s, 3H).  
13C NMR (126 MHz, Chloroform-d): 187.9, 153.9, 151.6, 143.8, 135.0, 129.0, 






HRMS (ESI, m/z): Calcd. for C15H14NO5 [M+H]+: 288.0872 Found: 288.0878 
 
Synthesis of 4-hydroxy-5-methoxy-2-nitrobenzaldehyde, Nitro-Vanillin (18) 
 
 
6-Nitro-o-benzylvanillin 35a (4.12 g, 14.3 mmol) was dissolved in acetic acid (30 
mL, 99%), and heated to 85 °C. 48% HBraq (15 mL) was added to the mixture and stirred 
for 3 h. The mixture was poured into ice water and extracted with EtOAc three times. The 
combined organic layers were washed with saturated NaHCO3, brine and dried over 
Na2SO4. The solvent was evaporated under reduced pressure. The crude product was 
purified by flash column chromatography using 20% to 60% EtOAc:Hexanes to yield the 
desired product 36 as dark brown liquid (0.65 g, 23% over two steps). The spectral data 
were in agreement with the reported data10.  
Rf = 0.50 (40% EtOAc:Hexanes). 














o-Hydroxy-6-nitrovanillin 36 (880 mg, 4.46 mmol) and K2CO3 (617 mg, 4.46 
mmol) were dissolved in DMF (15 mL). Compound 33 (1.68 g, 4.46  mmol) was added 
to the above solution.  The reaction mixture was stirred at 60°C overnight before being 
concentrated. Then, the crude mixture was poured into a solution of saturated NH4Cl 
(300 mL) and extracted with EtOAc three times and dried over Na2SO4. The solvent was 
evaporated under reduced pressure and the crude product was purified by flash column 
chromatography using 40% to 80% EtOAc:Hexanes to yield the desired product 38 as 
brown oil (659 mg, 30%).  
Rf = 0.50 (75% EtOAc:Hexanes).  
1H NMR (500 MHz, Chloroform-d): 10.43 (s, 1H), 7.70 (s, 1H), 7.39 (s, 1H), 
4.35 - 4.29 (m, 2H), 3.99 (s, 3H), 3.95 - 3.90 (m, 2H), 3.75 - 3.70 (m, 2H), 3.69 - 3.59 (m, 
8H), 3.59 - 3.54 (m, 2H), 3.52 (t, J = 6.7 Hz, 2H), 3.44 (t, J = 6.6 Hz, 2H), 1.76 (m, 2H), 
1.62 - 1.53 (m, 2H), 1.48 - 1.30 (m, 4H).  
13C NMR (126 MHz, Chloroform-d): 187.9, 153.7, 152.0, 143.81, 125.7, 110.1, 
108.9, 77.4, 71.4, 71.1, 70.8, 70.7, 70.2, 69.5, 69.5, 56.8, 45.2, 32.7, 29.6, 26.8, 25.6.  











Compound 37 (610 mg, 1.24 mmol) was dissolved in 1:1 MeOH:Dioxane (16 
mL). NaBH4 (85.3 mg, 2.25 mmol) was added portionwise at 0°C. The mixture was 
stirred at room temperature (rt) for 2 h. Then, the mixture was poured into water, 
neutralized with a 1 M solution of HClaq and extracted with DCM three times. The 
combined organic layers were dried over Na2SO4 and the solvent was evaporated under 
reduced pressure. The crude product was purified by flash column chromatography using 
3% to 5% MeOH:DCM to yield compound 38 as brown oil in quantitative yield (613 
mg).  
Rf = 0.55 (5% MeOH:DCM).  
1H NMR (500 MHz, Chloroform-d): 7.76 (s, 1H), 7.16 (s, 1H), 4.94 (s, 2H), 4.24 
(m, 2H), 3.96 (s, 3H), 3.93 - 3.88 (m, 2H), 3.75 - 3.59 (m, 10H), 3.56 (m, 2H), 3.52 (t, J = 
6.7 Hz, 2H), 3.44 (t, J = 6.7 Hz, 2H), 2.81 (s, 1H), 1.80 - 1.70 (m, 2H), 1.58 (p, J = 6.8 
Hz, 2H), 1.46 - 1.31 (m, 4H).  
13C NMR (126 MHz, Chloroform-d): 154.5, 147.3, 139.6, 132.8, 111.2, 110.2, 





O O O O Cl
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HRMS (ESI, m/z): Calcd. for C22H36ClNNaO9 [M+Na]+: 516.1976 Found: 
516.1971 
 
Synthesis of 4-((18-chloro-3,6,9,12-tetraoxaoctadecyl)oxy)-5-methoxy-2-nitrobenzyl 
(3-(4-((2,4-diaminopyrimidin-5-yl)methyl)-2,6-dimethoxyphenoxy)propyl)-




Compound 38 (430 mg, 0.870 mmol), 4-nitrophenyl chloroformate (263 mg, 1.31 
mmol), and DMAP (210 mg, 1.74 mmol) were dissolved in DCM (5 mL). The solution 
was stirred at room temperature (rt) under nitrogen atmosphere overnight.  
 Compound 25, TMP-NHBoc (430 mg, 0.992 mmol) was deprotected by directly 
dissolving in 4 mL of TFA:DCM (1:3) and stirring at rt for 2 h. Then, excess TFA was 
removed and co-evaperated with DCM several times under high vacuum to yield the 
TMP-NH2 TFA salt as a light brown solid. Rf = 0.02 in 10% MeOH:DCM. The primary 
amine salt can be stained on TLC using Ninhydrin solution, a pink spot close to baseline 
appeared upon heating. The crude TMP-NH2 TFA salt was dissolved in a mixture of 
DIEA (150 µL) and DCM (2 mL) and subsequently added to the above solution 












H O O O O Cl
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stirred at rt under nitrogen atmosphere overnight. The reaction was quenched with water 
(10 mL), concentrated under high vacuum before being extracted with DCM three times. 
The combined organic layers were dried over Na2SO4 and the solvent was evaporated 
under reduced pressure. The crude product was purified by flash column chromatography 
using 2% to 20% MeOH:DCM to yield compound 6 as brown viscous oil (120 mg, 16% 
over two steps).  
Rf = 0.70 (15% MeOH:DCM).  
1H NMR (500 MHz, Chloroform-d): 7.71 (s, 1H), 7.50 (s, 1H), 6.99 (s, 1H), 6.38 
(m, 3H), 5.79 (s, broad, 1H), 5.48 (s, 2H), 4.20 (t, J = 4.8 Hz, 2H), 4.02 (t, J = 5.5 Hz, 
2H), 3.88 (m, 3H), 3.84 (s, 3H), 3.77 (s, 6H), 3.69 (m, 2H), 3.66 - 3.57 (m, 10H), 3.54 
(m, 2H), 3.48 (m, 4H), 3.42 (t, J = 6.6 Hz, 2H), 1.90 (p, J = 5.7 Hz, 2H), 1.78 - 1.68 (m, 
2H), 1.55 (p, J = 6.8 Hz, 2H), 1.46 - 1.27 (m, 4H).  
13C NMR (126 MHz, Chloroform-d): 163.2, 156.2, 154.1, 153.6, 147.3, 139.6, 
135.6, 133.3, 129.1, 110.5, 110.1, 105.2, 71.9, 71.3, 70.9, 70.6, 70.6, 70.6, 70.1, 69.45, 
69.0, 63.3, 56.3, 56.1, 45.1, 39.4, 34.4, 32.6, 29.5, 26.7, 25.5.  

















Synthesis details for Scheme 4.2 
 
 Compound 25, 29, 33, and 38 were previously synthesized. 
 
Synthesis of tert-butyl (3-(4-((2-amino-4-((((7-(diethylamino)-2-oxo-2H-chromen-4-
yl)methoxy)carbonyl)amino)pyrimidin-5-yl)methyl)-2,6-dimethoxyphenoxy)propyl)-




30b was synthesized using a modified procedure reported by Nadler et al12. 
Briefly, previously synthesized 7-Diethylamino-(4-hydroxymethyl)coumarin, 
DEACM-OH, 29 (150 mg, 0.607 mmol) was dissolved in dry THF, added DIEA (0.2 mL, 
1.21 mmol), and then stirred for 10 min at 0 °C.  After dropwise addition of cold 
phosgene (1 mL, 1.50 mmol, 15 wt % solution in toluene), stirring was continued under 
the exclusion of light at 0 °C for additional 2 h. The reaction mixture was transferred onto 
a mixture of EtOAc and ice-cold H2O (1:1 v/v, 200 mL), the liquid was separated and the 
organic layer was dried over Na2SO4. The solvent was removed under reduced pressure 
and the crude [7-(diethylamino)-coumarin-4-yl]-methylchloroformate was further dried 
under high vacuum conditions.  
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In a separate flask, a solution of the TMP-NBoc (25, 132 mg, 0.303 mmol) in 
DCM (2 mL) was treated with DIEA (0.2 mL, 1.21 mmol) and DMAP (0.303 mmol, 37.0 
mg), and then stirred for 10 min at 0 °C. The previously prepared [7-(diethylamino)-
coumarin-4-yl]-methyl chloroformate was dissolved in DCM (1 ml) and slowly added to 
the reaction mixture of TMP-NBoc, 25, DIEA, and DMAP. The reaction mixture was 
stirred, protected from light and allowed to reach rt overnight. The reaction mixture was 
then transferred onto a mixture of DCM and water (1:1 v/v, 300 mL), the layers were 
separated, the organic layer washed with H2O (1 x 100 mL), saturated aqueous NH4Cl 
solution (2 x 100 mL), and brine (1 x 100 mL) and dried over MgSO4. The solvent was 
removed under reduced pressure and the crude mixture was purified by column 
chromatography with silica gel (2% to 20% MeOH:DCM) to yield 30 mg (15 %) of 
product 30b as dark brown solid.  
Rf = 0.30 (10% MeOH:DCM).  
UV-Vis (λmax in 20% DMSO/PBS buffer pH 7.4): 239, 282, 381 nm. 
1H NMR (600 MHz, DMSO-d6): 9.83 (s, 1H), 8.05 (s, 1H), 7.41 (dd, J = 9.1, 5.2 
Hz, 1H), 6.67 (t, J = 5.4 Hz, 1H), 6.62 (dd, J = 9.2, 2.6 Hz, 1H), 6.49-6.46 (m, 5H), 6.18 
(s, 1H), 5.32 (s, 2H), 3.86-3.73 (m, 4H), 3.69 (s, 6H), 3.36 (q, J = 6.9 Hz, 4H), 3.11 (q, J 
= 6.6 Hz, 2H), 1.71 (p, J = 6.8 Hz, 2H), 1.35 (d, J = 3.9 Hz, 9H), 1.07 (t, J = 7.0 Hz, 6H).  
13C NMR (126 MHz, DMSO-d6): 162.5, 160.9, 160.2, 156.6, 155.9, 155.7, 153.0, 
152.5, 151.1, 150.5, 135.7, 134.8, 125.3, 114.6, 108.8, 105.7, 105.3, 104.9, 96.9, 77.5, 
70.7, 61.8, 55.8, 44.1, 37.5, 33.4, 30.1, 28.3, 12.3 
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HRMS (ESI, m/z): Calcd. for C36H47N6O9 [M+H]+: 707.3405 Found: 707.3405 
 
Synthesis of tert-butyl (3-(2-(2-(3-aminopropoxy)ethoxy)ethoxy)propyl)carbamate 
(39) 
 
The known 39 was synthesized according to the reported procedure11.  
Briefly, bis(3-aminopropyl)diethylene glycol (26.85 g, 26.7 mL, 122 mmol) was 
dissolved in 1,4-dioxane (50 mL) and a solution of Boc-anhydride (4.37 g, 23.5 mmol) in 
dioxane (30 mL) was added dropwise at room temperature within 5 h. The mixture was 
stirred for additional 5 h and then the solvent was evaporated. The resulting yellowish oil 
was dissolved in water (50 mL) and extracted with DCM (4 × 50 mL). The organic 
phases were combined and washed with brine (4 × 30 mL). The extraction procedure and 
the subsequent washing were repeated. The resulting organic solution was dried 
(MgSO4), which subsequently was filtered off to give colorless oil after evaporation and 
drying under high vacuum (4.86 g, 65% rel. to Boc2O). TLC indicated only traces of 
doubly protected diamine (Rf = 0.95, 10% MeOH:DCM) and no starting material. The 
spectral data were in agreement with the reported data11.  
Rf = 0.70 (10% MeOH:DCM).  
1H NMR (500 MHz, Chloroform-d): 5.11 (s, 1H), 3.67 - 3.46 (m, 13H), 3.31 - 
3.07 (m, 5H), 2.86 (t, J = 6.6 Hz, 2H), 1.76 (m, 4H), 1.41 (s, 9H). 
BocHN O O O NH2
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13C NMR (126 MHz, Chloroform-d): 156.3, 79.0, 70.7, 70.7, 70.6, 70.3, 70.2, 
69.7, 69.6, 39. 8, 38.6, 32.1, 29.8, 28.6. 
HRMS (ESI, m/z): Calcd. for C15H32N2O5 [M+Na]+: 343.2209 Found: 343.2209 




Compound 38 (1.79 g, 3.624 mmol), 4-nitrophenyl chloroformate (1.10 g, 5.435 
mmol), DIEA (1.3 mL, 7.247 mmol), and DMAP (0.44 g, 3.624 mmol) were dissolved in 
DCM (18 mL). The mixture was stirred at room temperature (rt) under nitrogen 
atmosphere overnight.  
 Next, compound 39 (1.16 g, 3.624 mmol) and DIEA (0.6 mL, 3.624 mmol) were 
dissolved in DCM (5 mL), and then added to the above solution containing compound 38, 
which had been stirred overnight. The reaction mixture was continued stirring at rt for 
another 16 h. The reaction was quenched with H2O (20 mL) and partitioned into two 
layers. The organic phase was extracted with saturated aqueous NH4Cl solution (2 x 20 
mL), brine (1 x 20 mL), and dried over MgSO4. The combined organic layers were 
evaporated under reduced pressure. The crude mixture was purified by flash column 
chromatography with silica gel using 2% to 20% MeOH:DCM to yield the product 40 as 
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Rf = 0.60 (5% MeOH:DCM).  
1H NMR (500 MHz, Chloroform-d): 7.76 (s, 1H), 6.99 (s, 1H), 5.58 (s, 1H), 5.47 
(s, 2H), 4.96 (s, 1H), 4.23 (t, J = 4.9 Hz, 2H), 3.93 (s, 3H), 3.92 - 3.84 (m, 2H), 3.71 (dd, 
J = 6.1, 3.6 Hz, 2H), 3.69 - 3.40 (m, 34H), 3.33 (q, J = 6.1 Hz, 2H), 3.20 (q, J = 6.3 Hz, 
2H), 1.83 - 1.68 (m, 7H), 1.58 (p, J = 6.9 Hz, 2H), 1.42 (s, 13H), 1.39 - 1.29 (m, 3H). 
13C NMR (126 MHz, Chloroform-d): 156.2, 154.1, 147.5, 139.8, 128.8, 110.6, 
110.2, 79.0, 77.4, 71.4, 71.0, 70.8, 70.8, 70.7, 70.7, 70.3, 70.3, 70.2, 69.8, 69.7, 69.6, 
69.2, 63.4, 56.4, 45.2, 39.6, 38.6, 32.7, 3, 29.6, 29.5, 28.6, 26.8, 25.5. 




nyl)-3,19-dioxo-2,8,11,14-tetraoxa-4,18-diazadocosan-22-oic acid (41) 
 
 
Compound 41 was synthesized by modification of a procedure described by 
Passemard et al2. 
To a solution of 40 (1.15 g, 1.368 mmol) in 5 mL anhydrous DCM at 0 °C was 
slowly added TFA (5 mL, 130 mmol). Thereafter the reaction mixture was warmed to 
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TLC analysis, the solvent was removed under high vacuum to obtain the crude product as 
a TFA salt, which was used in the next step without further purification. 
To a solution of the above deprotected product in DCM (5 mL) was slowly added 
DIEA to adjust the pH until >7 and added a catalytic amount of DMAP (33 mg, 0.2737 
mmol). Subsequently, the above mixture was added succinic anhydride (166 mg, 1.66 
mmol) followed by stirring overnight at rt. Next, the reaction mixture was diluted with 
DCM (5 mL), washed with 1 M aqueous solution of HCl (3x5 mL) followed by brine. 
The organic layer was dried over MgSO4 and concentrated under vacuum to afford 41 
(1.04 g, 90%, two steps) as brown oil, Rf = 0.40 (10% MeOH:DCM), which was used in 
the next step without further purification. 
 
Synthesis of (7-(diethylamino)-2-oxo-2H-chromen-4-yl)methyl (2-amino-5-(4-((1-(4-
((18-chloro-3,6,9,12-tetraoxaoctadecyl)oxy)-5-methoxy-2-nitrophenyl)-3,19,22-
trioxo-2,8,11,14-tetraoxa-4,18,23-triazahexacosan-26-yl)oxy)-3,5-dimethoxybenzyl)-
pyrimidin-4-yl)carbamate, CTNH (9) 
 
 
Compound 30b (30 mg, 0.04244 mmol) was deprotected by directly dissolving in 2 
mL of TFA/DCM (1:2) and stirring at room temperature (rt) for 2 h. Next, excess TFA was 
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the TFA salt as a light brown solid. Rf = 0.02 in 10% MeOH/DCM. The primary amine salt 
can be stained well on TLC by Ninhydrin solution, the pink spot close to baseline appeared 
upon heated. The crude product was used in the next step without further purification. 
The crude mixture above was dissolved in 1 mL of DMF followed by addition of 
DIEA (100 µL) and stirring at room temperature (rt) for ~15 minutes. In a separate flask, 
a 1 mL solution of 41 (54 mg, 0.06367 mmol) in DMF, DIEA (100 µL), and HATU (28 
mg, 0.07428 mmol) were stirred at rt for ~10 minutes and then mixed with the above 
stirring mixture of deprotected DEACM-TMP-NH2. The mixture was then stirred at rt for 
another 16 h before being concentrated under high vacuum. The crude brown oil was 
dissolved in DCM (50 mL) and washed with saturated NH4Cl solution, brine, and dried 
with anhydrous Na2SO4. The crude mixture was then concentrated under reduced 
pressure and purified by silica gel column chromatography using 2% to 15% 
MeOH:DCM to yield pure product 9 (30%) as a brown oil.  The product was further 
purified by preparative HPLC using H2O/acetonitrile gradient. 
Rf = 0.40 (10% MeOH:DCM).  
UV-Vis (λmax in 20% DMSO/PBS buffer pH 7.4): 250, 311, 397 nm. 
1H NMR (500 MHz, DMSO-d6) : 9.96 (s, 1H), 8.01 (s, 1H), 7.77 (s, 1H), 7.76 - 
7.68 (m, 4H), 7.44 (m, 2H), 7.38 (s, 1H), 7.16 (s, 1H), 6.67 (m, 2H), 6.60 (s, 1H), 6.57 (d, 
J = 4.1 Hz, 2H), 6.52 (t, J = 3.0 Hz, 2H), 6.43 (d, J = 10.7 Hz, 2H), 6.17 (s, 1H), 6.13 (s, 
1H), 5.29 (d, J = 9.5 Hz, 5H), 4.18 (t, J = 4.5 Hz, 2H), 3.88 (s, 3H), 3.77 (m, 6H), 3.73 -
3.64 (m, 11H), 3.64 - 3.54 (m, 7H), 3.54 - 3.23 (m, 61H), 3.16 (m, 5H), 3.04 (m, 4H), 
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2.26 (s, 4H), 1.76 (d, J = 2.7 Hz, 3H), 1.72 - 1.52 (m, 9H), 1.52 - 1.39 (m, 2H), 1.39 -1.15 
(m, 7H), 1.10 (t, J = 7.0 Hz, 11H). 
13C NMR (126 MHz, DMSO-d6) : 171.2, 171.2, 168.9, 162.3, 155.8, 155.7, 
155.6, 155.0, 153.5, 152.9, 152.9, 152.8, 151.4, 150.4, 146.9, 139.3, 134.9, 134.5, 128.0, 
125.4, 125.3, 111.8, 110.8, 109.5, 108.7, 108.7, 106.0, 105.7, 105.2, 104.8, 104.6, 96.8, 
70.5, 70.4, 70.1, 69.9, 69.8, 69.8, 69.7, 69.5, 69.5, 69.4, 68.7, 68.5, 68.0, 67.8, 62.2, 61.7, 
61.1, 56.2, 55.9, 55.8, 45.3, 44.0, 37.6, 35.9, 35.8, 33.2, 32.9, 32.0, 30.9, 29.8, 29.6, 29.3, 
29.0, 26.1, 24.9, 22.6, 12.3. 














General methods for biology 
 
Dimerizer treatment and storage.  
Dimerizers were typically dissolved in DMSO at 10 mM and stored in amber 
plastic microcentrifuge tubes at −80 °C for long-term storage. For experiments, an aliquot 
was diluted in cell culture medium to final working concentration (10 µM for NTH and 
CTH, 100 nM for TNH, and 20 µM for CTNH, unless otherwise stated) and kept at −20 
°C, then warmed to 37 °C when ready to use. Care was taken to minimize exposure of 
dimerizers to light and heat before experiments. Working quickly in low brightness of 
white light, LED red light installed, or low levels of red filtered light used for differential 
interference contrast (DIC) microscopy did not cause detectable premature cleavage of 
our dimerizers. However, CTNH is more prone to photouncaging. 
 
Plasmids.  
All plasmids in this study are derived from pEM705, which contains a CAG 
promoter for constitutive expression, obtained from E.V. Makeyev (Nanyang 
Technological University, Singapore)13. More information about plasmids used in this 
thesis can be found in our published data14-16. For plasmids in prepared manuscript 





No. Plasmid name Components 
1 Halo-GFP-ActA 
C-terminal 47 amino acids of the Listeria 
monocytogenes ActA gene, conferring 
mitochondrial outer membrane targeting. 
2 mCherry-eDHFR 
mCherry fused to N-terminus of E. Coli 
dihydrofolatereductase (eDHFR) 
3 PEX3-GFP-Halo 
N-terminal 42 amino acids of the human Pex3 




Residues 1-175 of rat Kinesin-1 light chain, 
augmented with motor and motor effector 
domains 
5 Halo-GFP-SPC25 SPC25 sequence fused to C-terminus of Halo-GFP 
6 mCherry-eDHFR-Mad1 





CAAX motif fused to GFP-Halo C-terminus 
 
 
Cell culture and cell lines.  
All experiments were performed with HeLa acceptor cells as described13, 
originally obtained from E.V. Makeyev, Nanyang Technological University, Singapore13. 
Cells were cultured in growth medium (Dulbecco’s modified Eagle’s medium with 10% 
FBS and 1% penicillin–streptomycin, all purchased from ThermoScientific, Life 
Technologies) at 37 °C in a humidified atmosphere with 5% CO2. All cell experiments 
were performed with either stably or transiently transfected with a plasmid for bicistronic 
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expression of mCherry–eDHFR and indicated Haloenzyme-GFP constructs as the 
following protocols. 
Stable cell lines were created by recombinase-mediated cassette exchange using 
the HILO recombinase-mediated cassette exchange (RMCE) system14. Briefly, a 
monoclonal HeLa acceptor cell line with LoxP and Lox2272 recombination sites at a 
single chromosomal locus was co-transfected with a donor plasmid containing a 
transgenic cassette flanked by LoxP and Lox2272 sites and a Cre recombinase expressing 
plasmid, followed by antibiotic selection for a marker in the donor cassette. Cells were 
cultured as described above until reaching ~60% confluency. In a single well of a 6-well 
plate cells were transfected with 1 µg of donor plasmid and 10 ng of Cre plasmid, 
pEM784 (the Lampson lab) using either 3 µl of Fugene 6 (Promega) or Lipofectamine 
2000 (ThermoFisher). Two days after transfection, 1-2 µg/ml puromycin was added to the 
growth medium for the selection of stable cell lines. The transfected cells were grown for 
~7-14 days to select for a single colony. Transient transfections were performed as 
described above using 1 µg of plasmid DNA and a transfection reagent of choice, 24-48 h 
prior to imaging experiments. 
A cell line stably expressing Haloenzyme-GFP fused to CENP-B was used in 
Figure 2.8, 3.3, and 4.5. A stable cell line stably integrated with CENP-B-GFP-Halo-
IRES-mCherry-eDHFR was used in Figure 2.9, 2.10, and 4.8. All mitochondrial 
recruitment assays were performed using a stable cell line constitutively expressing Halo-
GFP-Mito-IRES-mCherry-eDHFR. The plasma membrane recruitment (Figure 4.8B) 
was performed using transient transfection of GFP-Halo-CAAX-IRES-mCherry-eDHFR 
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plasmid. Peroxisome recruitment experiments (Figure 3.6, 3.7, and 4.9) were performed 
by transiently transfecting either BICD-mCherry-eDHFR or KLC1-mCherry-eDHFR 
plasmid into cells stably expressing PEX3-GFP-Halo. 
The kinetochore experiments (Figure 4.10) were performed with Haloenzyme-
GFP-tagged kinetochore proteins (SPC25) stably expressed in cell lines. The top 5% 
GFP-positive cells were sorted with flow cytometry. The mCherry-eDHFR-Mad1 
plasmid was transiently transfected into the stable kinetochore GFP-positive cells using 
Lipofectamine 2000, 24 h before imaging following the manufacturer’s protocol. 
Hoechst staining was used to verify absence of bacterial contamination. 
 
Dimerizer cytotoxicity assay.  
AlamarBlue (Molecular Probes, catalog no. DAL1100) cell viability assays were 
performed following the protocol provided by the manufacturer (Thermo Fisher 
Scientific). The assay is based on conversion of a water-soluble dye, resazurin, into a 
fluorescent and colorimetric indicator by metabolically active cells. Damaged and 
nonviable cells generate lower signal due to reduced metabolic activity. HeLa cells were 
cultured in a 96-well assay plate (Corning Incorporated Costar, 3603), ~1 × 104 cells per 
well. Cells were treated with various concentrations of a dimerizer. In the same plate for 
each experimental replicate, DMSO (vehicle) was used as a positive control and either 
Blasticidin S HCl (10 µg/mL; Thermo Fisher Scientific, catalog no. A1113903) or 
Camptothecin (Sigma Aldrich) was used as a negative control. The final DMSO 
concentration was kept at 0.5% for CTH and TNH, and 1% for CTNH in 100 µL media 
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across all wells. After incubating with the dimerizers for 24 h or 48 h, cells were washed 
once with 200 µL of fresh DMEM, then incubated with the AlamarBlue reagent (10× 
dilution in DMEM medium) for 2 h to allow conversion of resazurin to resorufin. The 
fluorescence signal was measured at 37 °C with 550 nm excitation and 590 nm emission 
wavelengths, using a Tecan plate reader (model, Infinite M1000 PRO) operated by Tecan 
i-control software. The fluorescence signal was background subtracted based on wells 
without cells and calculated as a percentage of the signal from DMSO control cells. Each 
dimerizer concentration was tested in quadruplicate, and data were averaged over three 
independent experiments.  
 
Image acquisition.  
For live imaging, cells were seeded on 22 × 22 mm glass coverslips (no. 1.5; 
Fisher Scientific) coated with poly-D-lysine (Sigma-Aldrich) in single wells of a six-well 
plate. When ready for imaging, coverslips were mounted in magnetic chambers 
(Chamlide CM-S22-1, LCI) with cells maintained in L-15 medium without phenol red 
(Invitrogen) supplemented with 10% FBS and 1% penicillin–streptomycin at 37 °C on a 
heated stage in an environmental chamber (Incubator BL; PeCon GmbH). Images were 
acquired with a spinning disk confocal microscope (DM4000; Leica) with a ×100 1.4 NA 
objective, an XY Piezo-Z stage (Applied Scientific Instrumentation), a spinning disk 
(Yokogawa), an electron multiplier charge-coupled device camera (ImageEM; 
Hamamatsu Photonics), and a laser merge module equipped with 488- and 593-nm lasers 
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(LMM5; Spectral Applied Research) controlled by MetaMorph software (Molecular 
Devices).  
Z-stacks for both GFP and mCherry channel were taken with 0.5 µm spacing for a 
total of 3 µm in plasma membrane, centromeres, mitochondria and kinetochore 
experiments, and a total of 5 µm thickness was taken for peroxisome motor experiments. 
The time interval and duration of acquisition were specified in the figures, except for 
Mad1 experiments, time series were taken with time interval and duration manually 
decided based on cell cycle progression. All mages were analyzed using ImagJ or Fiji17. 
 
Dimerization and photo-activation.  
For NTH, CTH, and CTNH experiments, cells were incubated with dimerizers at 
the concentration and duration as indicated in the figures, which was normally followed 
by a 30-min washout to remove unbound dimerizer. For TNH experiments, 100 nM TNH 
was added directly to cells on the microscope stage.  
For whole-cell photouncaging or photocleavage, UV light is from a mercury arc 
lamp (Osram HXP R 120W/45C Vis) was filtered through a 387/11 nm band pass filter 
(Semrock, part # FF01-387/11 as a component in a DAPI filter cube) and focused 
through the objective. 
For targeted uncaging or cleavage, photo-control was performed with an iLas2 
illuminator system (Roper Scientific), equipped with a 405-nm laser (CrystaLaser LC, 
model # DL405-050-O; output of 27 mW after fiber coupling) controlled using the iLas2 
software module within MetaMorph. For targeted irradiation with the 405-nm laser, a 
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region of interest was defined using MetaMorph. ~7% laser power and 20 repetitions 
were used for CTH and CTNH uncaging, and 8% laser power and 40 repetitions were 
used for TNH and CTNH cleavage, unless otherwise stated.  
 
Protein-ligand docking and alignment 
 Using the Autodock tool integrated in Docking Server 
(http://www.dockingserver.com) for protein-ligand docking, we prepared individual 
ligands, Trimethoprim (TMP) and Haloligand (HTag) with a small part of the linker that 
we use to make the CTNH dimerizer. Energy minimization and total charges of the 
ligand structures were performed using the PM6 calculation. The CTNH dimerizer 
structure was energy minimized using an MM2 calculation in Chem3D 15.0 to obtain the 
fully extended structure of the linker. Docking was performed according to the default 
parameter (Autogrid) set up and automatic determination of the known binding site of 
each protein-ligand complex based on individual PDB crystal structures (1RG7 for 
eDHFR and 1BN7 for HaloTag protein).  
 Next, the Coot software was used to manually align the coordinates of the CTNH 
dimerizer to the individual TMP and Haloligand to obtain the CTNH-bound ternary 
protein complex. The distance of the linker between TMP and Haloligand was measured 
using the Chimera software. The distance was determined to be ~35 Å. The 
superimposed ternary complex structure does not exhibit steric hindrance between the 
eDHFR and HaloTag proteins. The photocleavable portion of the linker was observed 
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1H-15N HMBC NMR spectrum of 26 in DMSO- d6 (600 MHz);  
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3C NMR spectrum of 9 in DMSO-d6 (126 MHz) 
